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Effective Refractory Periods in the Right Atrium in Patients with
Atrioventricular Nodal Reentrant Tachycardia
TAKASHI TOKANO,1 YUJI NAKAZATO,1 KAORU KOMATSU,2 TAKESHI SUZUKI,2 HIDEMORI HAYASHI,2
GAKU SEKITA,2 YASUNOBU KAWANO,2 KAORU NAKAZATO,2 MASATAKA SUMIYOSHI,3 HIROYUKI
DAIDA2
From 1Department of Cardiology, Juntendo University Urayasu Hospital; 2Department of Cardiology, Juntendo
University School of Medicine; 3Department of Cardiology, Juntendo University Nerima Hospital, Japan
TOKANO ET AL.: Effective Refractory Periods in the Right Atrium in Patients with Atrioventricular Nodal
Reentrant Tachycardia. Introduction: Atrial flutter and fibrillation (AFL/AF) are frequently induced in patients
with atrioventricular nodal reentrant tachycardia (AVNRT), however, its mechanism is uncertain. The purpose of this
study was to determine characteristics of effective refractory periods in the right atrium (RA) in patients with AVNRT.
Methods and Results: In 26 patients with typical AVNRT (21 female, mean 46-year-old), AFL/AF was induced in
9 (35%) patients during an electrophysiologic study before slow pathway (SP) ablation. The atrial effective refractory
periods (A-ERP) were measured at the high, mid and low lateral wall in the RA, the high and mid RA septum, and the
SP region. Dispersion in the A-ERP (the longest − shortest; ERPD) was also calculated. The data was compared with
28 patients with intra- or infra-nodal atrioventricular block (AVB) and 32 patients with sinus node dysfunction
(SND). The mean A-ERP was from 196 to 220 msec excepting at the SP region. The A-ERP at the SP region was
significantly longer comparing with those at the other sites (mean 242 msec, p<0.05). Similar tendency was found in
patients with SND, not in patients with AVB. The ERPD was significantly greater than that in patients with AVB
(mean 72 versus 45 msec, respectively, p<0.05) while it was similar to that in patients with SND (mean 78 msec).
Conclusion: In patients with AVNRT, the A-ERP in the SP region was relatively prolonged and the ERPD was wide
as in patients with SND. These atrial electrophysiologic abnormalities might be potentially arrythmogenesis for
atrial tachyarrythmias other than AVNRT. (J HK Coll Cardiol 2012;20:31-37)
Atrioventricular nodal reentrant tachycardia, Atrial flutter, Atrial fibrillation, Refractory periods
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ATRIAL REFRACTORINESS AND AVNRT

Introduction
Atrioventricular nodal reentrant tachycardia
(AVNRT) is a common supraventricular tachyarrhythmia
in the clinical setting. An electrophysiologic study (EPS)
is performed for its diagnosis, usually before slow
pathway (SP) ablation. Previous studies have reported
that atrial flutter and/or fibrillation (AFL/AF) are
frequently complicated and induced during the EPS
in patients with AVNRT.1-8 However, the details of
AFL/AF coexistence with AVNRT is still not clear.
The purpose of this study is to determine
electrophysiologic characteristics of the right atrium
(RA), especially effective refractory periods and its
dispersion, in patients with AVNRT.

Methods
The study subjects were 26 patients with a typical
(slow-fast form) AVNRT and structurally normal heart
in whom an EPS and subsequent SP ablation were
performed. Twenty-one patients were female and
remaining 5 patients were male. The age was 46.1±14.9
(range 21-76) year-old. All patients did not have a
natural history of AFL/AF. The patients with underlying
cardiovascular disease such as coronary artery disease,
cardiomyopathy, valvular heart disease, hypertension
and the other kind of arrhythmias were not included in
this study subject. Therefore, patients who showed
abnormal findings on the chest X-rays, baseline 12 leads
electrocardiogram and echocardiogram were excluded
in this study.
The baseline EPS was performed using standard
techniques at unsedated fashion. Briefly, quadpolar
electrodes catheters were placed at the high RA, His
bundle region and the right ventricular apex. A decapolar
electrodes catheter was placed in the coronary sinus. To
minimize the effect of pacing on the atrial refractoriness,
atrial effective refractory periods (A-ERP) in the six
different sites in the RA were measured using the atrial
extra-stimuli at a basic cycle length of 600 msec with
10 msec gradual decrement moving a quadpolar
electrodes catheter at high, mid and low lateral wall in
the RA, high and mid RA septum, and low RA septum

32

(SP region). If an AVNRT was induced, it was
immediately terminated with an atrial or ventricular
burst pacing as soon as possible. Then, routine study
included an atrial burst pacing up to a rate of 200 pacing
per minute, sinus node overdrive suppression test, a
ventricular burst pacing and ventricular extra-stimuli
were performed. Inducibility of AFL/AF in the EPS that
lasted over 10 seconds was also noted. We defined the
dispersion in A-ERP (ERPD) as the difference in the
longest and shortest A-ERP among the six sites in the
RA. If AVNRT was not induced, subsequent provocative
EPS was performed. However, the all A-ERP data was
obtained before the routine baseline EPS.
The ERPD was compared with those in 28
patients with intra- and infra-Hisian atrioventricular
block (AVB) without episodes of any atrial
tachyarrhythmias (age: 76.8±10.5 year-old, 11 male)
and 32 patients with sinus node dysfunction (SND) (age:
77.0±10.4 year-old, 15 male). In the group of SND, AFL/
AF were clinically documented before the EPS in 15
patients (47%). In contrast, patients who had a history
of AFL/AF were not included in the group of AVB. In
these patients group, coronary sinus catheter was not
placed, however, A-ERPs in the RA and ERPD were
obtained using same technique in patients with AVNRT.
Inclusions for these patients group were indicated in
Table 1.
All patients were provided written consent to this
study approved by the institutional research ethics
committee.

Results
All patients showed a dual atrioventricular nodal
physiology and induced a typical AVNRT by using the
atrial burst pacing and/or extra-stimuli during the EPS.
No patients showed findings that indicated SND and
abnormal atrioventricular and intraventricular
conduction.
AFL/AF was induced in 9 (35%) patients. AFL
was induced in 3 patients, and AF was induced in
3 patients. In the remaining 3 patients, both AFL and
AF were induced. The intracardiac electrocardiogram
indicated that the earliest activation site at the
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onset of the induced AFL/AF was in the RA in all these
9 patients. The induced AFL/AF was not sustained
excepting for AFL in 1 patient, however, this sustained
AFL also spontaneously terminated within 1 minute.
A typical case was shown in Figure 1.
The A-ERP at the six sites in the RA in patients
with AVNRT were showed in Figure 2, and those in
all patient groups were shown in Figure 3. As shown

in Figures 2 and 3, the A-ERP at the SP region was
significantly longer comparing with those at the other
sites in the RA in patents with AVNRT (p<0.05). The
ERPD was calculated as 72.3±28.0 msec in the study
subjects (Figure 2). It was similar to that in patients
with SND, and there was a significant difference in
the ERPD between patients with AVNRT and AVB
(p<0.05, Figure 4).

Table 1. Inclusions for compared group of patients with sinus node dysfunction (SND) and atrioventricular
block (AVB)
Heart rate >60/min for patients with SND and >40/min AVB even if escape rhythm
Hemodymamically stable, no complication of heart failure
No continuous pacing is required
No marked atrial enlargement such as atrial diameter >45 mm
For patients with chronic AVB;
No history of atrial tachyarrhythmia
The study performed within 4 weeks from the occurrence of chronic AVB
The site of AVB was within or below the His-bundle

Panel A

Panel B

Figure 1. Intracardiac electrocardiogram in a typical case in which atrial flutter was induced.
This case was a 49 year-old male with a narrow QRS tachycardia in whom atrial flutter and fibrillation had not been documented.
During an electrophysiologic study, transient atrial flutter that lasted approximately 10 seconds was induced by an atrial extra
stimuli (basic cycle length: 600 msec, S1-S2: 210 msec, panel A). The clinical tachycardia was induced by a double atrial extra
stimuli (basic cycle length: 500 msec, S1-S2: 250 msec, S2-S3: 210 msec) under isoproterenol infusion that compatible with a
typical atrioventricular reentrant tachycardia (panel B).
II, V1: surface electrocardiogram, HRA: high right atrium, HBE: His bundle electrogram, CS: coronary sinus, RVA: right ventricular
apex, S: electrical stimulation, A: atrial activity, H: His-bundle activity, V: ventricular activity.
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Figure 2. The effective refractory periods at the six sites in the right atrium in 26 patients with atrioventricular nodal reentrant
tachycardia.
The atrial effective refractory periods at the slow pathway region was significantly longer comparing with those at the other sites
in the right atrium (RA) (p<0.05). The dispersion in effective refractory periods (ERPD) was calculated as 72.3±28.0 msec.
HLRA: high lateral RA, MLRA: mid lateral RA, LLRA: low lateral RA, HSRA: high septal RA, MSRA: mid septal RA,
CSOS: coronary sinus ostium, SVC: superior vena cava, IVC: inferior vena cava, TV: tricuspid valve.

Figure 3. The effective refractory periods at the six sites in the right atrium (RA) in patients with atrioventricular nodal
reentrant tachycardia, atrioventricular block and sinus node dysfunction.
The atrial effective refractory periods (A-ERP) with atrioventricular nodal reentrant tachycardia (AVNRT), intra- and infra-Hisian
atrioventricular block (AVB) without episodes of any atrial tachyarrhythmias, and sinus node dysfunction (SND) were shown.
HLRA: high lateral RA, MLRA: mid lateral RA, LLRA: low lateral RA, HSRA: high septal RA, MSRA: mid septal RA, SP: slow
pathway.
34
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Figure 4. Comparison of dispersion in the effective refractory periods in the right atrium among the patients group.
Dispersion in the effective refractory periods (ERPD) in patients with atrioventricular nodal reentrant tachycardia (AVNRT) was
similar to that in patients with sinus node dysfunction (SND), and there was a significant difference in the ERPD between patients
with AVNRT and SND comparing with patients who had intra- and infra-Hisian atrioventricular block (AVB) without episodes of
any atrial tachyarrhythmias (p<0.05).

Discussion
The major findings of this study was that transient
AFL/AF was induced in approximately one third of
patients with AVNRT, and the ERPD in the RA was
about the same as in patients with SND.
As in previous studies, paroxysmal AFL/AF is
frequently observed in patients with AVNRT.1,6 Before
catheter ablation era, Hurwitz et al described that AF
was documented in 26% patients with AVNRT during
10 years follow-up.1 Kimman et al reported that AFL/
AF was observed in 17% patients after successful slow
and/or fast pathway ablation for AVNRT.6 In addition,
AFL/AF was also frequently induced in patients with
AVNRT during EPS in the other previous studies.2,5,8
Razani et al reported that AF was induced in 8% of

J HK Coll Cardiol, Vol 20

patients with AVNRT who did not have a history of AF,
and the induction rate was increased to 67% if more
aggressive protocol for AF induction was employed.8 It
was not unusual that AVNRT initiates paroxysmal AF
in previous studies as well.4,7 Regarding to the study
reported by Sauer et al, AVNRT was induced in 4.3% of
patients with paroxysmal AF, and AF was cured by SP
ablation for AVNRT without pulmonary vein isolation
in most of those patients.7 This study did not include
the patients who had documented clinical episodes of
AFL/AF, however, the induction rate of transient AFL/
AF during an EPS in this study was similar to those in
previous studies.2,8
The inducing mechanism of AFL/AF in patients
with AVNRT is still not clear. Hurwitz et al suggested
that "so-called" remodeling of atrial tissue due to
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35

ATRIAL REFRACTORINESS AND AVNRT

sustained AVNRT may have caused AF.1 AF that was
degenerated from AVNRT might be related to this
mechanism. In this study, we terminated induced
AVNRT as soon as possible by atrial or ventricular burst
pacing. In some patients of the study subject, AFL/AF
was already induced before the first induction of
AVNRT (Figure 2), therefore, remodeling of atrial tissue
due to sustained AVNRT may be ruled out. Kimman et
al emphasized in their report that ablation lesion may
have related to the occurrence of AFL/AF as a new
arrhythmia after slow and/or fast pathway ablation.6
However, most of previous studies and our study
demonstrated that frequent AFL/AF induction was
observed before ablation, therefore, this mechanism is
not considerable. Decrease in the vulnerability to pacinginduced AF after SP ablation may have direct or indirect
effect on AF substrate.8 The study suggested the effect
of SP ablation on atrial vagal tone.8 The SP contributes
to the reentrant circuit for AVNRT, however, it exists in
atrial tissue surrounding the compact atrioventricular
node, but not within the compact atrioventricular node
itself. Regarding that the SP is an abnormal atrial tissue,
it may play a role as slow conduction zone for the other
kind of atrial reentrant tachycardia such as AFL/AF.
Kimman et al also pointed out that 4 patients had preexisted type 1 AFL and the AFL was cured with ablation
technique for AVNRT,6 while the other study showed
no effect of SP ablation on inducibility of AFL.2 If so,
the ERPD in the RA might be wide in patients with
AVNRT.
On the other hand, SND is considered to be an
atrial disease which is frequently complicated with AFL/
AF. Expanded ERPD in the RA myocardium may be
related to the occurrence of AFL/AF as shown in
previous studies.9-13 Our previous report also found that
the ERPD was significantly wider in SND if it was
compared with that in patients without AFL/AF such as
the patients who had only intra-Hisain and infra-Hisian
conduction disturbance.13 This study demonstrated that
the ERPD in patients AVNRT was wider comparing to
almost the same control group of patients with SND,
and the relatively longer A-ERP at the SP region may
contribute to the wider ERPD.

36

Study Limitation
In patients with AFL/AF, the left atrial tissue and
pulmonary veins are also arrhythmia origin. We did not
discuss about the A-ERP in the left atrium in this study.
However, all induced AFL/AF showed that the earliest
activation site at the onset was in the RA, not in the
coronary sinus. So, induced AFL/AF that was
considered to be the left atrium origin was not included
in this analysis. Therefore, the results and discussion in
this study were reasonable for AFL/AF that was
originated from the RA and complicated in the patients
with AVNRT. In addition, detail RA mapping to identify
the reentrant circuit of induced AFL/AF employing Halo
catheter or electroanatomical mapping system was not
performed in this study, therefore, it was not proved
that prolonged A-ERP at the SP region and relatively
wide ERPD in the RA was directly related to the
occurrence of AFL/AF.
The results of this study were potentially
influenced by several factors. This study was not
controlled study. The patients with AVB were not
"true" control group. Regarding to the A-ERP in the
patients with AVB, those were relatively longer
comparing with the patients with AVNRT. It indicated
that the patients with AVB could not be treated as "a
normal RA group". Long lasting bradycardia,
artificial pacing and heart failure may have caused
atrial electorophisiologic change and affected on the
results of this study. The data should have been
compared with that in the "true" control group with
completely normal heart such as younger patients
who underwent an EPS for evaluation of syncope
unknown origin, however, obtaining ERPD data from
comparable number of such patients was very difficult
in the clinical setting. Therefore, we carefully
selected these patients as a patients group that had
not AFL/AF minimizing the potential impacts on the
study results other than unavoidable age difference
due to general patient population as shown in Table
1, and the comparison in this study was considered
to be also meaningful. Pacing maneuver and induction
of AVNRT may have also influenced on the A-ERP.
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Therefore, the measurement of A-ERP was already
completed before routine EPS was done without any
pharmacological interventions. If AVNRT was induced
during the measurement of A-ERP, it was immediately
terminated as described in the methodology.
The number of patients in the study was relatively
small, so further patients collection was required for
more discussion such as relationship to induced and
especially clinical AFL/AF.

Conclusion
The A-ERP in the RA surrounding the SP was
relatively prolonged and the ERPD in patients with
AVNRT was as wide as in patients with SND. These
atrial electophysiologic abnormalities might be
potentially arrythmogenic for atrial tachyarrythmias in
patients with AVNRT despite unuseful AV nodal
modification.
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A Rare Cause of Cardiac Tamponade: Hypereosinophilic Syndrome
KWOK-LEUNG WU, KIN-LAM TSUI, KA-LAI LEE, SUNG-YU LIU, KWOK-KEUNG CHAN, SHU-KIN LI
From Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong
WU ET AL.: A Rare Cause of Cardiac Tamponade: Hypereosinophilic Syndrome. We describe a male adult
patient who presented with chest discomfort and shortness of breath. A diagnosis of cardiac tamponade was made by
transthoracic echocardiogram. Urgent pericardiocentesis was performed and analysis of pericardial fluid showed
presence of eosinophil. Complete blood picture showed peripheral eosinphilia as well. Subsequent work up for
eosinophilia showed ova of Clonorchis sinesis from the stool thus a course of praziquantel was given. Transient
clinical improvement and lowering of eosinophil count were observed but two weeks later he developed acute coronary
syndrome. Urgent coronary angiogram showed coronary vasospasm. Endomyocardial biopsy was performed afterwards
which showed marked eosinophilic infiltrate. Bone marrow biopsy and skin biopsy showed marked marrow eosinophilia
and leucocytoclastic vasculitis with abundant eosinophils, respectively. A diagnosis of hypereosinophilic syndrome
was made after exclusion of secondary and clonal eosinophilia. After oral steroid was given, his condition was
stabilized and the eosinophil count was normalized. (J HK Coll Cardiol 2012;20:38-42)
Cardiac tamponade, Hypereosinophilic syndrome, perimyocarditis, prednisolone, vasospasm

Introduction
Hypereosinophilic syndrome (HES) is a rare
entity characterized by overproduction of eosinophils
resulting in end-organ damage. We report a case of HES
presented with cardiac tamponade, impaired left

ventricular systolic function and acute coronary
syndrome due to vasospasm. The case illustrates the
diagnostic and treatment approach to this condition. It
also illustrates the dilemma in management when
the patient was also diagnosed to have coexisting
Clonorchiasis as an alternative cause of eosinophilia.

Case Report
Address for reprints: Dr. Kwok-Leung Wu
Department of Medicine, Pamela Youde Nethersole Eastern
Hospital, 3 Lok Man Road, Chai Wan, Hong Kong
Email: wukwokleung@hotmail.com
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A 51-year-old gentleman, who had history of
asthma, presented with chest pain for 2 days. On arrival
to the casualty department his blood pressure was
75/50 mmHg, pulse 120 bpm, and the oxygen saturation
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was 97% while on 4 Litre oxygen. Electrocardiogram
(Figure 1) showed sinus tachycardia 112 bpm. Chest
X-Ray showed cardiomegaly. Dopamine infusion was
given. Blood result showed total white cell count
13.1x109/L, neutrophil count 4.6x109/L, lymphocyte count
1.5x109/L and eosinophil count 6.2x109/L (47.6% of total
white cell count). Echocardiogram demonstrated mildly
depressed left ventricular systolic function with left
ventricular ejection fraction around 40%, and pericardial
effusion with signs of cardiac tamponade. Urgent
pericardiocentesis was performed. The chest pain
subsided and the hemodynamic status was stabilized
afterwards.
Echocardiogram was repeated on the next day
which showed moderately impaired left ventricular
systolic function and the left ventricular ejection fraction
measured around 40%. Mild tricuspid regurgitation was
noted. No pericardial effusion was detected. Analysis
of pericardial fluid revealed presence of eosinophil. A
review of the patient's previous admission record
showed that his eosinophil count was already raised
(3.7x109/L) seven months before this admission, when
he was admitted for an asthmatic attack. Further workup
for eosinophilia was performed, which included
checking of autoimmune markers (including antineutrophil cytoplasmic antibody) and tumor markers.

All these results were negative. Stool was saved for
parasites. Nerve conduction study was performed
because he complaint of occasional numbness over
bilateral lower limbs, which showed no evidence of
vasculitic polyneuropathy. High resolution computer
tomography of thorax showed only non-specific ground
glass densities. Subsequently the stool culture yielded
ova of Clonorchis sinesis. A course of oral praziquantel
was given. Empirical steroid therapy was not started
because of proven parasitic infection. Before discharge
his eosinophil count was slightly lowered from 6.2
to 5.1x109/L (46.7% of total white cell count).
Two weeks later this gentlemen presented to
the casualty department again for chest pain.
Electrocardiogram showed ST segment depression over
the chest leads V4-6. Serum troponin level was elevated
up to 0.16 ng/dL. Total white cell count was 16.9x109/L
and eosinophil count was 8.3x10 9 /L (49.1%). A
diagnosis of acute coronary syndrome was made. Urgent
coronary angiogram (Figure 2) revealed coronary
vasospasm over the posterolateral artery and right
posterior descending artery, which was relieved by
intracoronary nitrate and verapamil injection.
Endomyocardial biopsy was performed several
days later in view of persistent peripheral eosinophilia,
which showed myocarditis associated with marked

Figure 1. Echocardiographic finding of pericardial effusion.
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eosinophilic infiltrate. Bone marrow aspiration and
trephine biopsy demonstrated marked marrow
eosinophilia. During admission this patient was noted
to have patchy erythematous rash with sharp
demarcation over bilateral lower limbs. Skin biopsy
showed leucocytoclastic vasculitis with marked
eosinophilic infiltrate. Stool culture was repeated which
showed no growth. The diagnosis of hypereosinophilic
syndrome was made. Blood for RT-PCR FIP1L1PDGRFα fusion (reverse transcription polymerase chain
reaction for the fusion of Fip1-like gene and plateletderived growth factor receptor alpha) was checked
which was negative.
Oral prednisolone 60 mg per day was then given.
The eosinophil count was normalized after several days.
Cardiac magnetic resonance imaging (MRI) was
performed before discharge which revealed moderately
impaired left ventricular systolic function (left
ventricular ejection fraction was 36.1%). There was also
diffuse scarring in the ventricular wall which suggested
cardiac involvement in HES. During follow up he
remained asymptomatic and the eosinophil count
remained normal. Oral prednisolone was tailed down
to 5 mg daily and the plan was to keep this dosage for
longer period of time. Follow up cardiac MRI at 4

months after discharge showed improvement in left
ventricular systolic function and moderate resolution
of myocardial scarring.

Discussion
This patient presented with cardiac tamponade,
impaired left ventricular systolic function and acute
coronary syndrome due to coronary vasospasm. All
these features could be explained by acute eosinophilic
myocarditis which was proven by endomyocardial
biopsy. Peripheral eosinophilia was noted and several
end organs were involved. Eosinophilia can be
categorized into secondary (caused by parasitic
infestations, vasculitis, drug and lymphoma), clonal
(presence of histological, cytogenetic, or molecular
evidence of underlying myeloid malignancy) an
idiopathic (such as HES) types.1 It is essential to identify
the type of eosinophilia because subsequent
management may be very different. Hypereosinophilic
syndrome, a subcategory of idiopathic eosinophilia, is
defined by the presence of a peripheral blood eosinophil
count of 1.5x109/L or greater for at least 6 months,
exclusion of both secondary and clonal eosinophilia and

Figure 2. Coronary angiogram showed coronary vasospasm over the posterolateral artery and right posterior descending artery
(left panel), which was relieved by intracoronary nitrate and verapamil injection (right panel).
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evidence of end organ involvement.
In this case a secondary cause for eosinophilia
was present, which was infestation by Clonorchiasis.
This posed diagnostic and treatment dilemma and
rendered steroid therapy inappropriate in the initial
status. However, as HES carries high morbidity
and mortality, treatment by systemic steroid or
immunosuppressive agents should be initiated once the
infestation was cleared. In this case despite initiation of
praziquantel, the patient developed recurrent symptom
with rebound of the eosinophil count. During the second
admission stool culture was negative. In fact peripheral
eosinophilia in Clonorchiasis seldom exceeds 10 to 20%
and the infestation is primarily, if not exclusively,
confined to the hepatobiliary system. The eosinophil
count was around 40% of total white cell count in this
case. Multi-organ involvement was proven by
histological analysis. This implied that infestation by
Clonorchiasis was only a clinical bystander in this case.
Apart from the bronchodilators and the inhaled
corticosteroid, this patient did not take other
medications. Hematological malignancy was excluded
by the bone marrow examination. Another important
differential diagnosis in this case was vasculitis,
especially Churg-Strauss syndrome (CSS). This case did
not completely fulfill the classification criteria of CSS,
because it only fitted into 3 (1st, 2nd and 5th ) out of 6
criteria by the American College of Rheumatology (need
to fulfill 4 out of 6 criteria): 1) Asthma; 2) Eosinophil
>10%; 3) Mono/polyneuropathy; 4) Paranasal sinus
pathology; 5) Histological proof of eosinophils in
extracellular space; 6) Migratory pulmonary opacities.2
On the other hand, anti-neutrophil cytoplasmic antibody
(ANCA) was negative in this case which render the
diagnosis of CSS less likely.
This patient had a peripheral blood eosinophil
count greater than 1.5x109/L for longer than 6 months.
There was evidence of multi-organ involvement as well,
manifested as acute eosinophilic myocarditis,
eosinophilic bone marrow infiltrate and leucocytoclastic
vasculitis. Secondary and clonal eosinophilia were less
likely in this case. Therefore the most likely diagnosis
was HES.
Cardiac involvement is a major cause of
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morbidity and mortality among patients with HES.3
Cardiac involvement usually presented as intra-cardiac
thrombus formation and endomyocardial fibrosis
causing restrictive cardiomyopathy. Cardiac magnetic
resonance imaging (MRI) and echocardiography are
able to detect fibrosis, eosinophilic infiltrate and thrombi
to stage the fibrotic evolution of the disease. Treatment
for heart failure, anticoagulation, immunosuppressive
therapy are the mainstay of management. The 5-year
mortality is estimated to be 30%.4 Loeffler's endocarditis
is a separate entity from HES.5 However, effects of
eosinophils on the heart may go through different stages
of initial necrotic phase with intense myocarditis, and
associated arteritis (Loeffler's endocarditis) followed by
thrombotic stage and finally endomyocardial fibrosis.
Pericardial involvement as in this case, is rare in
HES. In retrospect, pericardial or endomyocardial
biopsy should be considered during the initial
presentation, in order to start timely therapy. Spiegel
et al6 reported a case of eosinophilic pericarditis of an
18-month-old child who presented with eosinophilic
pericarditis causing cardiac tamponade requiring
pericardiocentesis. The child recovered after prolonged
systemic steroid therapy. Tan and Duggal7 also reported
a case with similar scenario in a 56-year-old female.
Although coronary vasospasm could occur in HES, in
this case the ST change and modest rise in troponin
could be accounted by eosinophilic cardiomyopathy
alone, and coronary vasospasm was only a laboratory
phenomenon. It was because one should expect ST
elevation in case of coronary vasospasm, instead of ST
depression in this case. Takahashi et al reported a case
of acute myocardial infarction in a young man with
history of HES. Coronary angiogram was performed
which showed vasospasm over the left anterior
descending artery. 8 The mechanism by which
eosinophils induce coronary spasm could be related
to massive infiltration of eosinophils into
endomyocardium and the deposition of their granular
proteins (such as eosinophilic cationic protein) which
may increase vascular tone or irritability.9
Bone marrow biopsy is important to exclude
secondary eosinophilia due to lymphoma, clonal
eosinophilia and the malignant variants of HES, the
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myeloproliferative variants and lymphocytic variants.10
Peripheral blood test for RT-PCR FIP1L1-PDGRFα
fusion was negative in our patient. A proportion of
patients with HES have an interstitial deletion on
chromosome 4q12 resulting in the fusion of two genes,
FIP1L1 and PDGFRα. Its presence indicates higher
likelihood of potentially fatal cardiac involvement.
Moreover, this group of patients will have response to
imatinib, a tyrosine kinase inhibitor.11 In such case
imatinib instead of steroid therapy should be started as
soon as possible to avoid rapid disease progression.
During follow up, features of end organ
involvement, thromboembolism and side effects arising
from steroid therapy should be looked for, and
eosinophil count should be monitored. Follow up
echocardiography and cardiac MRI are recommended
as well. For those on imatinib therapy, regular
monitoring of left ventricular systolic function is
necessary because it is known to cause left ventricular
systolic dysfunction.12

Conclusion
In summary, we reported a case of
hypereosinophilic syndrome with multiple cardiac
involvements. Apart from urgent pericardiocentesis to
relieve cardiac tamponade, recognition of this rare
disease entity, exclusion of secondary and clonal
eosinophilia, and appropriate steroid therapy is essential
for management of this potentially life-threatening
condition.
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IL1.
PROTEOMIC STUDY REVEALS PLASMA PROTEIN
CHANGES IN CONGENITAL HEART DISEASES AND
POTENTIAL CLINICAL SIGNIFICANCE
C Xuan,1 G Gao,1 XY Bai,1 XC Liu,1 Q Yang,1,2 GW He1,3
1
TEDA International Cardiovascular Hospital, Medical College, Nankai
University, Tianjin, China; 2Department of Medicine & Therapeutics, The
Chinese University of Hong Kong, Hong Kong; 3Department of Surgery,
Oregon Health and Science University, Portland, Oregon, USA
Objectives: Congenital heart disease (CHD) is the most common birth defect
in newborns. Plasma proteins may often serve as indicators of disease and is a
rich source for biomarker discovery but little has been studied in CHD, The
present proteomic study examined the hypothesis that plasma proteins may
be altered and related to the pathological changes of CHD. Such alternations
might be useful in development of biomarkers in the diagnosis and treatment
of CHD.
Methods: Differential protein analysis was performed in the plasma of patients
with tetralogy of Fallot (TOF), isolated ventricular septal defect (VSD) and
normal controls by using two-dimensional electrophoresis (2-DE) and mass
spectrometry. Candidate proteins that might be related to disease processes
were further confirmed by enzyme-linked immunosorbent assays (ELISA) in
the new samples (n=40).
Results: Eighteen differentially expressed protein sports and 10
corresponding proteins or polypeptides were identified by 2-DE and mass
spectrometry. Among those, two down-regulated proteins (gelsolin, ficolin3) has significant clinical relevance. Gelsolin is related to rapid platelet

activation and shape changes and ficolin-3 is a recognition molecule in the
lectin-pathway of the complement system and plays an important role in
innate immunity. These two proteins were further analyzed as candidate
proteins for validation and measured by ELISA. The plasma gelsolin
(76.3±4.42 vs. 131.80±23.46 µg/ml in control, P=0.025, n=40 in each group)
and ficolin-3 (4.93±0.36 vs. 10.58±1.58 µg/ml in control, P=0.001, n=40 in
each group) levels in TOF patients were significantly lower than those in
normal controls. The ficolin-3 plasma level was also lower in the patients
with isolated VSD (5.55±0.34 vs. 10.58±1.58 µg/ml in control, µg/ml,
P=0.003, n=40 in each group).
Conclusion: In the present study we have for the first time, by using
proteomic methods, demonstrated the plasma protein changes in CHD
patients. Our study may reveal the possible reasons for the prolonged
bleeding time in TOF patients and the susceptibility to pulmonary infections
in patients with CHDs.

IL2.
GENOME-WIDE ASSOCIATION STUDY IN HEART DISEASES:
PRINCIPLE AND APPLICATION
GW He,1,2 XY Bai,1 XC Liu,1 Q Yang1,3
TEDA International Cardiovascular Hospital, Medical College, Nankai
University, Tianjin, China; 2Department of Surgery, Oregon Health and Science
University, Portland, Oregon, USA; 3Department of Medicine & Therapeutics,
The Chinese University of Hong Kong, Hong Kong
1

Objective: In the past decade, the sequencing of the human genome provided
a route map to catalogue and interpret genetic variation among individuals.
The scale of diversity is vast, ranging from microscopically visible variation
at the level of individual chromosomes to variation at the deoxyribonucleic
acid (DNA) sequence level with nucleotide substitutions, insertions and
deletions, including >10 million SNPs (dbSNP, http:www.ncbi.nlm.nih/gov/
projects/SNP/). Submicroscopic structural variation, notably copy number
variation (CNV), is increasingly recognized and plays a critical role in
cardiovascular diseases. We studied patients with tetralogy of Fallot and
coronary artery disease with regard to reveal SNPs and CNVs.
Methods: We performed genome-wide CNVs analysis on TOF patients and
normal age-matched children using the Affymetrix SNP 6.0 Array (Affy6.0
array). Taqman assay was then performed in TOF patients or age-matched
control for validation of the CNVs identified by Affy6.0 array. The further
validation was performed by using Tagman qPCR assay. Two to three Taqman
probes were designed to detect each of the CNV regions in TOF patients
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and normal controls. The CNV loci from Taqman assay, which were
consistent with the GWAS results, were considered to be the successfully
identified CNVs. In coronary artery disease, we studied those with
myocardial infarction and arrhythmia.
Results: In 60 tetralogy of Fallot (TOF) patients and 60 age-matched and
870 other controls, we have found more that 20 rate CNVs that containing
encoding genes and more that 50 possible SNPs in TOF patients. The
validation study has been further performed to identify these CNVs. In
coronary artery disease, we studied 100 patients and control with myocardial
infarction and arrhythmia. The studies have also identified both CNVs and
SNPs.
Conclusions: Our studies have demonstrated that GWAS followed by
validation studies may successfully identify disease-causing genes in
congenital and coronary artery diseases. In particular, identifying rare CNVs
may reveal these disease-causing genes in congenital heart diseases.
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IL4.

ARE ALL ARBs CREATED EQUAL FOR BP LOWERING?

THE SLOWER, THE BETTER

G Bakris
The University of Chicago Medicine, Chicago, IL, USA

P Letcheur
Servier Pharmaceutical Research & Development Co. Ltd., Beijing, China

Drugs that inhibit the renin-angiotensin system (RAAS) are the cornerstone
of therapy for cardiovascular (CV) and kidney disease risk reduction because
they protect against worsening outcomes in the respective target organs.
However, there are eight ARBs and they differ in their BP lowering ability
and other pharmacodynamics effects. They are all well tolerated however,
with the lowest overall adverse effect profile of any of the antihypertensive
medications. Recent results from the ONTARGET study have confirmed that
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor
blockers (ARBs) confer similar cardioprotection, with little to no benefit of
the combination in CV disease. For renoprotection, it remains unclear whether
one class is superior to another, and dual RAAS blockade does not offer more
advantages over single agent blockade. Losartan and Irbesartan are the two
ARBs with indications for renal protection and telmisartan the only one FDA
approved for use when the patient is ACE intolerant. Azilsartan has the greatest
effect on BP lower of any of the ARBs and the only one combined with
chlorthalidone, the evidence based diuretic. Given that the FDA has indicated
that BP lowering is associated with CV risk reduction using an agent that will
insure maximal initial efficacy for BP reduction is warranted.

It has been a long journey since, in the late seventies, the discovery of
If current in sino-atrial node till ivabradine opens the path to an innovative
treatment for patients with Angina 20 years later. Resting heart rate is
considered today as a major cardiovascular risk factor for CAD and Heart
Failure. The SHIfT study demonstrated the beneficial effect of ivabradine on
outcomes in heart failure patients leading to new treatment guidelines in
Europe.

IL5.
DEVELOPMENT OF STEM CELL PRODUCT − "CELLGRAM"
HS Kim
Pharmicell Co., Ltd., Korea

The clinical application of the stem cell technology began with the first bone
marrow transplantation in 1956. This success led to the quantitative and
qualitative growth of stem cell therapy through bone marrow transplantation.
In the 1990's, the marrow stromal stem cell, one of the stem cells in the bone
marrow, began to be utilized in various ways. Of course, the study of the
properties of this stem cell has begun a long time ago. In Korea, the first
attempt was made in 1999 to overcome the mismatch of histocompatibility
by using the mesenchymal stem cell cultured from the donor's bone marrow
for bone marrow transplantation. In Korea, however, as the government
announced the definition of the cell therapy product in 2002, the regulation
set by the Korea Food and Drug Administration (KFDA) began, and since
then, all cell therapy products have needed to be licensed by the government.
Most of the leading researchers of the development of stem cell therapeutics
were doctors of that time. They established their own companies as a means
to go against the government regulation, and 'Pharmicell' was one of them.
Our company was established in 2002, and we prepared clinical trials that
were compatible with this regulation. Developers and government officials
needed to have a process for solving many difficult problems rationally. Stem
cell therapy products consist of live cells. Established methods for
manufacturing and quality control which have been suggested by the
government are not proper for stem cell products. For example, the potency
test is very important. It must include reproducible quantitative methods that
can represent the effect of the drugs. In 2005 after 4 years of preparation, the
application from Pharmicell for the clinical trial was submitted in regard to
the heart disease. The KFDA conducted preclinical study prior to the clinical
trial which means that the KFDA was willing to apply the fast track to medical
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products with these characteristics. The preclinical study clarified the procedure
and objective of the clinical trial to minimize errors of the clinical trial, thus
recognizing the results of clinical trials that were conducted in this way. It is
similar to the special protocol assessment (SPA) program of FDA in the USA.
As the IND phase III study had already been permitted for the ischemic stroke,
phase I for AMI was exempted, and phase II and III were permitted at the
same time. The clinical trial began in 2006. The mesenchymal stem cell
cultured from the autologous bone marrow was infused once intracoronarily.
The follow-up period is 6 months, and the primary end point was the
improvement of left ventricular ejection fraction, and the measurement method
was the radioisotope test, SPECT. At that time, MRI could not be used as it
was yet to be developed. A randomized, open labeled study was conducted.
Six months later no cardiac death or major toxicity related to medication was
found, and the SPECT test confirmed that the left ventricular ejection fraction
increased by 5.9% as compared to the pretreatment status. Patients who
succeeded in reperfusion within 6 hours after the AMI occurred accounted for
60% of all patients. These patients' left ventricular ejection fraction increased
by 8.3%, and the difference was statistically very significant. These results
indicated the possibility that, even though the stem cell product was injected
into the heart 4 weeks after the myocardial injury, the injured myocardium
could be recovered. In other words, the function of the myocardium around
the necrosis that is not completely disappeared can be improved after the
injection of our stem cell product. This finding supports the theory that the
anti-inflammatory effects, stem cell homing in tissues, angiogenesis and
fibrolysis act together rather than the stem cell product replacing tissues. The
long-term follow-up is now underway, five years after the start of the clinical
trial. Soon, we will be able to clarify the long-term effects or side-effects. At
the moment, our company (Pharmicell Co., Ltd.) is conducting clinical trials
for ischemic stroke (IND III) and spinal cord injury (IND II/III). By 2014, we
will be able to release the results of the clinical trials.

October 2012

J HK Coll Cardiol, Vol 20

ICSM, THE SIXTEENTH ANNUAL SCIENTIFIC MEETING
ABSTRACTS
Abstracts for Invited Lectures:
IL6.
MECHANISMS OF SOMATIC CELL REPROGRAMMING
MA Esteban
Chinese Academy of Sciences, Guangzhou, China
The generation of induced pluripotent stem cells (iPSCs) by defined exogenous
transcription factors represents a model system to understand the epigenetic
basis of mammalian cell fate determination and has remarkable implications
for regenerative medicine and disease modeling_ENREF_8. At present,
reprogramming is viewed as an inefficient multistep procedure in which a
series of exogenous (the extracellular millieu) and endogenous (the somatic
cell genetic program) barriers must be overcome to trigger the transition from
intermediate states to pluripotency_ENREF_13_ENREF_13. Improved
understanding of the molecular basis of these barriers and how they are
suppressed is relevant because it may facilitate higher fidelity of the conversion
through experimental manipulation. My talk will focus on the work our lab
has done in recent years to understand the mechanisms of mouse iPSC
generation.
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OP1.
LONG-TERM FENOFIBRATE THERAPY INCREASES
FIBROBLAST GROWTH FACTOR 21 AND RETINOLBINDING PROTEIN 4 IN SUBJECTS WITH TYPE 2 DIABETES
KL Ong, 1,2 KA Rye,1,2,3 R O'Connell,4 AJ Jenkins, 3,4 C Brown,4 A Xu, 5,6
DR Sullivan,7 PJ Barter,1,, AC Keech4
1
Lipid Research Group, Heart Research Institute, Sydney, Australia; 2Faculty
of Medicine, University of Sydney, Sydney, Australia; 3Department of
Medicine, University of Melbourne, Melbourne, Australia; 4National Health
and Medical Research Council Clinical Trials Centre, University of Sydney,
Sydney, Australia; 5Department of Medicine, The University of Hong Kong,
Hong Kong; 6Department of Pharmacology & Pharmacy, The University of
Hong Kong, Hong Kong; 7Department of Clinical Biochemistry, Royal Prince
Alfred Hospital, Sydney, Australia

Results: Relative to the placebo group, the changes of serum FGF21 and
RBP4 levels were 85% (P<0.001) and 10% (P=0.032) higher in the fenofibrate
group respectively over five years. Fenofibrate treatment had no detectable
effect on serum A-FABP level (P>0.05). The effect of fenofibrate treatment
on serum FGF21, but not RBP4, remained significant after adjusting for
fenofibrate-induced changes in glycosylated hemoglobin, total cholesterol,
triglycerides, apolipoprotein A-II, fibrinogen, plasma creatinine, and
homocysteine (P=0.002).
Conclusions: Long-term fenofibrate treatment could increase serum FGF21
levels over five years in patients with type 2 diabetes. Further studies are
needed to investigate the potential role of FGF21 in the fenofibrate-mediated
reduction of cardiovascular risk.

Introduction: Fenofibrate is a peroxisome proliferator-activated receptor
(PPAR)-α agonist which showed beneficial effects on total cardiovascular
risk in patients with type 2 diabetes in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study. This study aimed to investigate the longterm effect of fenofibrate therapy on three novel biomarkers of cardiovascular
risk, namely adipocyte-fatty acid binding protein (A-FABP), fibroblast growth
factor 21 (FGF21), and retinol-binding protein 4 (RBP4), which are all
downstream targets of PPAR-α or PPAR-γ, in patients with type 2 diabetes.
Methods: A total of 216 patients (108 in the fenofibrate group and 108 in
the placebo group) were randomly selected from the FIELD study cohort.
A-FABP, FGF21, and RBP4 levels were measured in serum samples at both
baseline and the fifth year of the study.

OP2.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
δ) MEDIATES THE VASCULAR BENEFITS OF
DELTA (PPARδ
METFORMIN IN DIET-INDUCED OBESE MICE
WS Cheang,1 XY Tian,1 WT Wong,1 CW Lau,1 Y Lu,1 X Yao,1 SST Lee,2
Y Huang 1
1
Li Ka Shing Institute of Health Sciences and School of Biomedical Sciences;
2
School of Life Sciences, The Chinese University of Hong Kong, Hong Kong
Objectives: Metformin, an anti-diabetic drug, is known to activate AMPactivated protein kinase (AMPK); whilst AMPK and PPARδ have been shown
to form a transcriptional complex and synergistically induce gene expression.
The present study investigated whether PPAR δ is a critical mediator for
metformin in ameliorating endothelial dysfunction in diet-induced obese
(DIO) mice.
Methods: Aortae from C57BL/6J mice were cultured with tunicamycin
[endoplasmic reticulum (ER) stress inducer], metformin, or GSK0660
(PPARδ antagonist). Male PPARδ wild-type and knockout mice were fed
with high-fat diet for 3 months to induce obesity, followed by oral
administration with metformin for 7 days. Vascular reactivity and protein
expression levels were determined by wire myograph and Western blotting,
respectively. Fluorescence imaging measured the levels of reactive oxygen
species (ROS) and nitric oxide (NO) under confocal microscopy.
Results: Tunicamycin impaired endothelium-dependent relaxations (EDR)
in response to acetylcholine, and increased the levels of ROS and ER stress
markers, such as phosphorylated eIF2α, ATF6 and ATF3 in mouse aortae.
These harmful effects of tunicamycin were reversed by co-treatment with
metformin while such benefits of metformin were abolished by GSK0660.

48

Chronic metformin treatment alleviated EDR and reduced the levels of ROS
and above-described ER stress markers in DIO PPARδ wild-type but not in
PPARδ knockout mice. Tunicamycin-induced reduction of NO production
in endothelial cells was also reversed by metformin.
Conclusions: The present study provides novel evidence that PPARδ plays
a critical role in the vascular benefits of chronic metformin treatment in
restoring the impaired endothelial function and curtailing ER and oxidative
stress in obese mice. Dual medication of metformin together with PPARδ
agonist could be a more effective venue against diabetic vasculopathy
(Supported by GRF grants).
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PR INTERVAL PROLONGATION STRONGLY PREDICTS
NEW-ONSET MYOCARDIAL INFARCTION, ISCHEMIC
STROKE, HEART FAILURE AND CARDIOVASCULAR
DEATH IN HIGH-RISK CARDIOVASCULAR PATIENTS:
PATHOPHYSIOLOGICAL INSIGHTS OF ADVERSE
VASCULAR FUNCTION
YH Chan, KK Lau, KH Yiu, YF Yiu, SW Li, TH Lam, CP Lau, CW Siu, HF Tse
Division of Cardiology, Queen Mary Hospital; and School of Public Health,
The University of Hong Kong, Hong Kong
Objectives: To investigate whether PR prolongation predicts adverse
cardiovascular (CV) events in coronary patients or risk equivalent, and the
underlying pathophysiological mechanisms in terms of vascular phenotypes.
Methods: We prospectively followed up 597 high-risk CV outpatients (mean
age 66±11 years; male 67%; coronary disease 55%, stroke 22%, diabetes
52%) for new-onset ischemic stroke, myocardial infarction (MI), congestive
heart failure (CHF), and CV death. Vascular phenotypes were assessed by
high-resolution ultrasound for mean carotid Intima-Media Thickness (IMT),
and Vascular Profiling System (VP-2000; subgroup n=338) for Pulse Wave
Velocity (PWV). Impaired left ventricular ejection fraction (LVEF) from
transthoracic echocardiography (subgroup n=194) was defined as <35%. PR
interval was determined from 12-lead electrocardiogram.

Results: PR prolongation >200 ms was present in 79 patients (13%) at baseline.
PR prolongation >200 ms was associated with significantly higher mean carotid
IMT (1.05±0.37 mm vs 0.94±0.28 mm, P=0.010, Figure 1), higher PWV
(1144±142 cms-1 vs 1091±143 cms-1, P=0.024), and impaired LVEF<35%
(16% vs 5%, P=0.027). After mean follow-up of 63±11 months, increased PR
interval significantly predicted new-onset ischemic stroke (P=0.006), CHF
(P=0.040), CV death (P<0.001), and combined CV endpoints (P<0.001) at
cut-off >200 ms, and new-onset MI (C-statistic 0.70, P=0.001) at >162 ms
(P=0.008). Adjusting for potential confounders using multivariable cox
regression, PR prolongation independently predicted increased risk of newonset ischemic stroke (HR 5.05, 95%CI: 1.34 to 19.10, P=0.017), CV death
(HR 16.40, 95%CI: 3.99 to 67.46, P<0.001, Figure 2), combined CV endpoints
(HR 2.33, 95%CI: 1.26 to 4.32, P=0.007) at cut-off >200ms, and increased
new-onset MI (HR 8.05, 95%CI: 1.66 to 39.06, P=0.010) at cut-off >162 ms.
Conclusions: PR prolongation >200ms strongly predicts new-onset ischemic
stroke, MI, and CV death, and combined CV endpoint including CHF in highrisk CV patients. Increased risk of MI was observed at PR interval >162 ms.
Whether adverse vascular function in PR prolongation may mechanistically
represent mediating pathways prior to clinical events warrants further
investigations.

Table 1. Prediction of New-Onset CV Events by PR Interval
New-Onset CV Events
n (%)
MI
Ischemic stroke
HF
CV death
Combined endpoints

Total
(n=597)
26 (4%)
21 (4%)
37 (6%)
27 (5%)
87 (19%)

Figure 1. PR interval and carotid IMT .
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PR Interval
<200 ms (n=518)
20 (4%)
14 (3%)
28 (5%)
17 (3%)
65 (13%)

PR Interval
>200 ms (n=79)
6 (8%)
7 (9%)
9 (11%)
10 (13%)
22 (28%)

P-value
0.130
0.006*
0.040*
<0.001*
<0.001*

ROC C-Statistic
Estimate
P-value
0.70
0.001*
0.50
0.99
0.60
0.042*
0.63
0.020*
0.61
0.001*

Figure 2. Kaplan-Meier curves for CV death.
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CIGARETTE SMOKE-INDUCED ANGIOGENESIS THROUGH
AMPK ACTIVATION IN RAT HEART
YM Liang,1 MSM Ip,1,3 JCW Mak1,2,3
Departments of 1Medicine and 2Pharmacology & Pharmacy, 3Research Centre
of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong,
Hong Kong

elevation of cardiac VEGF level (545.1±43.66 pg/mg protein and 722.6±
28.60 pg/mg protein for SA and CS group respectively, p<0.01) after CS
exposure. Western blot analysis showed a significant increase in the
phosphorylation of AMPK (Thr172).
Conclusion: Our data demonstrated that a pro-inflammatory state existed in
the heart of CS-exposed rat, leading to elevation of VEGF production. The
AMPK pathway might play a role in CS-induced angiogenesis.

Objectives: Vascular endothelial growth factor (VEGF) is recognized as an
angiogenic predictor. It has been reported that there is a link between VEGF
release and adenosine monophosphate (AMP)-activated kinase (AMPK)
activation in many cells (Fisslthaler B & Fleming I, Circ Res 2009; 105:114).
This study aims to investigate the effects of cigarette smoke (CS) on the levels
of VEGF, anti-inflammatory mediators, IL-10 and adiponectin, and AMPK
pathway in heart of CS-exposed rat.
Methods: Male Sprague-Dawley rats (aged 6-7 weeks) were randomly divided
into sham air (SA) group (n=8) and CS group (n=8) respectively. CS group
was exposed to 4% CS for 1h each day for 56 days in ventilated smoking
chambers, while the SA group was exposed to fresh air. Animals were sacrificed
24 h after the last exposure and heart tissue was collected. Heart homogenates
were prepared for the determination of IL-10 and adiponectin and VEGF by
ELISA and activation of AMPK by Western blot analysis.
Results: CS exposure caused significant decrease in the levels of cardiac
IL-10 (348.9±37.22 pg/mg protein and 259.5±16.73 pg/mg protein for
SA and CS group respectively, p<0.05) and cardiac adiponectin
(375.1±14.77 ng/mg protein and 270.9±31.67 ng/mg protein for SA and
CS group respectively, p<0.05). On the contrary, we found a significant

OP5.
cAMP/PKA-ACTIVATED CFTR IS REQUIRED FOR
ACIDOSIS-INDUCED RELEASE OF ATP FROM SKELETAL
MYOCYTES
L Lu,1 J Tu,2 HJ Ballard1
Department of Physiology, Li Ka Shing Faculty of Medicine, The University
of Hong Kong, Hong Kong; and 2 Shenzhen Institutes of Advanced
Technology, Chinese Academy of Sciences, Shenzhen, China

1

ATP is an extracellular signaling molecule involved in the regulation of skeletal
muscle blood flow.
Our previous study showed that depression of pH using lactic acid treatment
stimulated the efflux of ATP from skeletal myocytes through a mechanism that
involved the cystic fibrosis transmembrane conductance regulator (CFTR). The
present study was undertaken to further explore the signal transduction
mechanism linking the decrease in pH to the ATP release from muscle.

IBMX, suggesting that the PKA/cAMP pathway was involved in CFTR
activation. Furthermore, an in vivo phosphorylation study using 32P-ATP showed
that CFTR phosphorylation was increased by forskolin alone or foskolin with
dibutyryl-cAMP and IBMX, further supporting a role for the cAMP/PKA
pathway in CFTR activation in muscle. Amiloride, an inhibitor of the Na/H
exchanger (NHE), prevented the lactic-acid-induced increases in intracellular
cAMP and extracellular ATP; inhibitors of the Na/Ca exchanger (NCX), SN-6
and KB-R7943, also inhibited the lactic-acid-induced accumulation of ATP in
the medium surrounding the cultured myocytes.
Based on these data, we propose that depression of the pH increases the efflux
of ATP through a mechanism that involves CFTR activation through the cAMP/
PKA pathway, and that NHE and NCX may be involved.

Accumulation of ATP in the medium surrounding the myocytes was measured
using a luminescence assay. Incubation of the myocytes in lactic acid (10 mM)
for 3 hours increased the extracellular ATP from 0.67±0.08 to 1.15±0.11 nM
(n=36; P<0.001). The specific inhibitor of CFTR, CFTRinh-172, inhibited the
lactic-acid-induced increase in extracellular ATP. The CFTR expression was
significantly increased with 3 hours incubation with lactic acid. Lactic acid
treatment also increased the intracellular cAMP from 3.2±0.3 to 7.1±1.0 nM,
and the Protein Kinase A (PKA) activity from 30.6±4.5 to 37.0±5.4 pmol/ml,
whereas the lactic-acid-induced increase in extracellular ATP was inhibited by
the PKA inhibitor, KT5720, but enhanced by the phosphodiesterase inhibitor
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HIGH FERRITIN AND LOW TRANSFERRIN SATURATION
ARE ASSOCIATED WITH PRE-DIABETES AMONG ADULTS
CL Cheung, TT Cheung, KSL Lam, BMY Cheung
Department of Medicine, Li Ka Shing Faculty of Medicine, The University of
Hong Kong, Hong Kong
Background and Aims: Iron overload is known to cause diabetes. However,
the underlying mechanism is poorly understood. We therefore studied the
association of different markers of iron metabolism, namely ferritin, erythrocyte
protoporphyrin and transferrin saturation (TSAT, as defined by a percentage
of transferrin that is saturated with iron) with pre-diabetes (preDM) in US
adults without chronic kidney disease, anemia, and iron deficiency.
Methods: Data on 2,575 participants of the National Health and Nutrition
Examination Survey (NHANES) 1999-2002 who were free of diabetes, chronic
kidney disease, iron deficiency, and anemia were analyzed. Data on 3,876
participants of the NHANES III (1988-1994) were used as replication.
Homeostasis model assessment of insulin resistance (HOMA-IR), blood
glycosylated hemoglobin level (A1C), fasting glucose, insulin, and preDM
(defined as a fasting plasma glucose 100-125 mg/dl or an A1C value 5.76.4%) were measured as the outcomes.
Results: Logistic regression analyses indicated independent associations of
high ferritin (Ptrend=0.028) and low TSAT (Ptrend=0.029) with preDM after
adjusting for sociodemographics, physical activity (active/sedementary),
metabolic and inflammatory markers (triglycerides, total cholesterol, HDL
cholesterol, mean arterial pressure, CRP, white cell count, and albumin), and
liver enzymes (GGT, ALP, AST, and ALT). The NHANES III data showed

similar associations. Combining the results showed a more significant
association for high ferritin (P meta=0.016) and low TSAT (P meta=0.002).
Moreover, TSAT was associated with A1C, fasting glucose, insulin, and
HOMA-IR (Pmeta ≤0.001).
Conclusions: Higher ferritin and lower TSAT are associated with higher risk
of preDM in a general population without confounding diseases. Further
research is needed to examine the underlying mechanism of these two indices,
especially TSAT, in the pathophysiology of preDM.

OP7.
FUNCTIONAL ROLE OF TRPC5 CHANNELS IN AORTIC
BARORECEPTOR
EOC Lau, B Shen, CO Wong, Y Huang, X Yao
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong
Kong
Aortic baroreceptor is the mechanosensor to detect blood pressure in aortic
arch. Upon changes in arterial blood pressure, the baroreceptor nerve terminal
on the aortic arch adventitia will be activated, resulting in action potentials
that propagate to the cardiovascular control centre in the brain. However,
the molecular identity of the baroreceptor mechanosensors is not well
understood.
TRP channels are a superfamily of non-selective cation channels that can be
divided into seven subfamilies: TRPA, TRPC, TRPM, TRPML, TRPN, TRPP,
and TRPV. Many TRP isoforms have been reported to be sensors for diverse
source of external and/or internal stimuli. Recently, one of the isoforms,
TRPC5, has been reported to be hypo-osmolarity and pressure sensitive.

hypotonicity-induced [Ca2+]i response while a TRPC5 blocking antibodies
T5E3 inhibited the response. Electrophysiological studies showed that
hydrostatic pressure could activate the whole-cell current in cultured
baroreceptor neurons and the current displayed a double rectifying I-V
relationship, which is typical of TRPC5. Daidzein treatment also potentiated
the pressure-induced action potential firing in isolated aortic baroreceptor
neurons, which could be blocked by a TRPC blocker 2-APB. Furthermore,
trpc5 knockout mice manifested a significant reduction in aortic depression
nerve activity upon blood pressure elevation when compared with wildtype mice.
Taken together, our study provides the evidence that TRPC5 is involved in
pressure sensing of aortic baroreceptor neuron and is participated in the
aortic baroreceptor function.

In the present study, the expression of TRPC5 channels in the aortic
baroreceptor nerve terminal, which is located on the aortic arch, along the
nerve fiber (aortic depressor nerve) and in the ganglion region (nodose
ganglion) was demonstrated by immunohistochemistry. RT-PCR and
immunoblot studies confirmed the expression of TRPC5 channels in the
aortic baroreceptor. In Ca2+ imaging studies of cultured aortic baroreceptor
neurons, a TRPC5 potentiator daidzein was able to potentiate the
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ANGIOTENSINOGEN (M235T) GENE AND BLOOD
PRESSURE RESPONSE TO ACE INHIBITOR (ENALAPRIL)
IN PATIENTS WITH ESSENTIAL HYPERTENSION
K Srivastava,1 S Chandra,1 J Bhatia,2 R Narang,3 D Saluja3
Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi;
Departments of 2Pharmacology and 3Cardiology, All India Institute of Medical
Sciences, India

1

Objective: We determined the association of angiotensinogen (M235T) gene
polymorphism with essential hypertension and the relationship between
polymorphism in the angiotensinogen (M235T) gene and blood pressure
response to ACE inhibitor (Enalapril) in patients with essential hypertension.
Methods: 250 patients with essential hypertension and 250 controls from
Delhi and surrounding areas were recruited for the investigation. Blood
pressure was recorded before and after 6 weeks of treatment with ACE
inhibitors, Enalapril. Genotyping were carried out by polymerase chain
reaction and Restriction fragment length polymorphism technique.
Results: Statistically significant association of T allele was observed with
essential hypertension [x2=14.67, p=0.00013, odds ratio=1.76 (1.3-2.32) at
95% CI]. The decrease in systolic and diastolic blood pressure after six
weeks of treatment of the patients carrying TT genotype were greater than
the groups carrying MT and MM genotypes.
Conclusions: The angiotensinogen (M235T) gene polymorphism is
significantly associated with essential hypertension. Patients carrying TT
genotype had higher blood pressure lowering response when treated with
ACE inhibitor, Enalapril than those carrying MM and MT genotypes
suggesting that the T allele may be a possible genetic marker for essential
hypertension.
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CP1.
C-REACTIVE PROTEIN TRENDS AND ASSOCIATIONS
WITH TOTAL MORTALITY IN UNITED STATES ADULTS
BETWEEN 1999-2010
KL Ong,1,2 MA Allison,3 BM Cheung,4 BJ Wu,1 PJ Barter,1,2 KA Rye1,2,5
1
Lipid Research Group, Heart Research Institute; 2Faculty of Medicine,
University of Sydney, Sydney, Australia; 3Department of Family and
Preventive Medicine, University of California San Diego, La Jolla, CA,
United States; 4Department of Medicine, The University of Hong Kong,
Hong Kong; 5Department of Medicine, University of Melbourne, Melbourne,
Australia
Introduction: C-reactive protein (CRP) is a well-known biomarker of
systemic inflammation. Elevation of CRP levels is predictive of incident
cardiovascular disease morbidity and mortality. We investigated the trends
in prevalence of elevated CRP levels (>3.0 mg/L), as well as mean CRP
levels, in a general population of United States adults and then determine
the associations with mortality.
Methods: Data from the 27,214 subjects aged ≥20 years in the National
Health and Nutrition Examination Survey (NHANES) 1999-2010 were
analyzed. Among them, 12,259 subjects from NHANES 1999-2004 had
mortality data followed up through December 31, 2006.
Results: After adjusting for age, sex, race/ethnicity, body mass index, and
medications for lowering blood pressure, glucose and lipids, the prevalence
of elevated CRP decreased significantly from 36.7% in 1999-2002 to
32.0% in 2007-2010, corresponding to a decrease in mean CRP levels from
1.92 to 1.66 mg/L (both P<0.001). The trend remained significant after
additional adjustment for several traditional cardiovascular risk factors and

use of medications, including statins, angiotensin-converting enzyme
inhibitors, metformin, aspirin and clopidogrel. However, the decreasing
trends were attenuated after additional adjustment for total bilirubin
(P=0.076 and 0.024), which increased from 0.62 to 0.73 mg/dL over 12
years (P<0.001). Of note, higher CRP levels were modestly associated with
a higher risk of total mortality (adjusted hazard ratio: 1.07 [95%CI, 1.031.12] per 10 mg/L increase, P=0.001), and this association tended to be
stronger in subjects with higher total bilirubin levels (P for interaction
<0.001).
Conclusion: The decreasing trend of CRP levels is encouraging and may be
related to the increase in total bilirubin levels. Such trends may be explained
in part by the increasing use of some medications such as statins that can
increase bilirubin levels and decrease CRP levels. Moreover, the prediction
of total mortality by CRP levels seems to be stronger in subjects with higher
total bilirubin levels.

CP2.
ACTIVATION OF ANGIOTENSIN CONVERTING ENZYME2 RESCUES ENDOTHELIAL FUNCTION BY OXIDATIVE
STRESS REDUCTION IN DB/DB DIABETIC MICE
Y Zhang, J Liu, XY Tian, L Wang, WT Wong, CW Lau, Y Huang
Institute of Vascular Medicine, School of Biomedical Sciences, The Chinese
University of Hong Kong, Hong Kong
Objective: Angiotensin converting enzyme-2 (ACE2), a new member of
the vasoprotective axis of the renin-angiotensin system, is a pleiotropic
exopeptidase that plays a regulatory role in cardiac and vascular physiology.
The present study investigates whether ACE2 activation improves endothelial
function in type 2 diabetic mice and explores the potential participating
cellular events.
Methods: 12-week-old male db/db mice were orally administered with ACE2
activator diminazene aceturate (DIZE, 15 mg/kg/day) for 2 weeks. Wire
myograph was utilized to measure isometric force of isolated aortae, while
DHE and CM-H2DCFDA fluorescence were used to determine the reactive
oxidative species (ROS) generation in aortae and endothelial cells. In
addition, ACE2 activity was assayed by Mc-Ala/Dnp fluorescence resonance
energy transfer (FRET) assay.
Results: Chronic treatments with DIZE in db/db mice were able to reduce
systolic blood pressure and increase ACE2 activity without affecting the
insulin and glucose tolerance. In vivo DIZE treatment restored the impaired
endothelium-dependent relaxations (EDRs) in response to acetylcholine and
lowered oxidative stress in aortae of diabetic mice. In addition, ex vivo
experiments show that 24-hour treatment with DIZE (100 µgmol/L) not only
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improved EDRs in db/db mouse aortae, but also prevented the impairment
of EDR by high glucose (30 mmol/L) or angiotensin II (Ang II, 500 nmol/L)
in normal C57BL/6 mouse aortae. The beneficial effects of DIZE were
counteracted by ACE2 inhibitor DX600 and Mas receptor blocker A779,
and absent in ACE2 knockout mice. Furthermore, both ex vivo and in vitro
treatment with DIZE normalized ROS over-production in the endothelium
of db/db mouse aortae and in high glucose- or Ang II-treated human umbilical
vein endothelial cells. Such effects of DIZE were also inhibited by ACE2
inhibitor and ACE2 siRNA transfection.
Conclusions: This study provides novel evidence that ACE2 activator can
rescue the impaired endothelial function in diabetic mice largely through
reducing the elevated oxidative stress in the endothelium. Our results suggest
that activating ACE2-Ang(1-7)-Mas signaling could be another promising
therapeutic option against diabetic vascular dysfunction. (Supported by Hong
Kong GRF).
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ENDOTHELIN-1 CONTRIBUTES TO ENDOTHELIUMDEPENDENT CONTRACTIONS IN ZUCKER FATTY RATS
J Liu, XY Tian, WT Wong, LM Liu, Y Zhang, L Wang, Y Huang
Institute of Vascular Medicine, School of Biomedical Sciences, The Chinese
University of Hong Kong, Hong Kong

Conclusion: The present study provides showed a contributory role of ET-1
in endothelial dysfunction in Zucker fatty rats and the effect of ET-1 is likely
mediated by ETAR/p38 MAPK/COX-2 signaling cascade. Our results
highlight potential efficacy of ET receptor blockers in preserving endothelial
function in metabolic syndrome (Supported by Hong Kong GRF).

Objective: Cardiovascular disease is the leading cause of patients with
metabolic syndrome and endothelin-1 (ET-1) is shown to be closely
associated with cardiovascular disease. However, whether ET-1 participates
in endothelial dysfunction in metabolic syndrome is not well established.
The present study aims at investigating the pathological role of ET-1 in
vasculopathy in metabolic syndrome.
Methods: Six-month old Zucker lean rats and Zucker fatty rats were orally
treated with or without ET-1 receptor antagonist bosentan for one month
and then sacrificed. Renal arteries were dissected out and endotheliumdependent contractions (EDCs) were measured in wire myograph. Some
renal arteries were kept for Western blotting to detect the expression of ET
type A receptor (ETAR), p38 AMPK and cyclooxygenase-2 (COX-2).
Results: EDCs in response to acetylcholine in L-NAME-treated arteries were
augmented in Zucker fatty rats compared with Zucker lean rats and were
suppressed following chronic bosentan treatment. Overnight incubation with
bosentan, ETAR antagonist ABT627, p38 MAPK inhibitor SB203580 and
COX-2 inhibitor NS398 all reduced EDCs in Zucker fatty rats. Moreover,
overnight exposure to ET-1 exaggerated EDCs in arteries from Zucker lean
rats, which was inhibited by ABT627, SB203580 or NS398. Western blotting
showed an increased phosphorylation of p38 MAPK and up-regulation of
COX-2 upon ET-1 treatment.

CP4.
LYCIUM BARBARUM POLYSACCHARIDES MITIGATE
CHRONIC INERMITTENT HYPOXIA INDUCED
HIPPOCAMPAL OXIDATIVE STRESS, INFLAMMATION AND
APOPTOSIS IN RATS
CS Lam,1 GL Tipoe,2 RCC Chang,2 KF So,2 KH Cheung,1 ML Fung1
Departments of 1Physiology and 2Anatomy, The University of Hong Kong,
Hong Kong
Background: Chronic intermittent hypoxia (CIH), mimicking severe
conditions of obstructive sleeping apnea, induces oxidative stress,
inflammation and apoptosis in the hippocampus. Lycium barbarum
polysaccharides (LBP) are biological significant portions of traditional
Chinese herbal medicine Goji, which possess anti-oxidative and antiinflammatory properties.
Objectives: Our study aims to investigate the neuroprotective effect of LBP
in CIH rats. We hypothesize that LBP ameliorate oxidative stress,
inflammation and apoptosis in the hippocampus of rats exposed to CIH.
Methods: MDA assay was used to measure the lipid peroxidation extent, a
marker of oxidative stress. Western blot was employed to examine the
expressions level of antioxidant enzymes (SOD-1, SOD-2); inflammatory
mediators (IL-1β], TNFα, COX-2); caspase-dependent extrinsic (FADD,
caspase 8, Bid) and intrinsic apoptotic (Bax, Bcl2, cytochrome C) cell death
(cleaved caspase 3) cascades; proliferative marker (PCNA) and trophic factor
(BDNF). In situ cell death staining (TUNEL) was utilized to reveal the
apoptotic situation of hippocampal subfields (DG, CA1 and CA3).
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Results: LBP administrations remarkably attenuated the level of oxidative
stress, inflammation and apoptosis in the hypoxic group. In addition, LBP
significantly mitigated caspase-dependent apoptotic extrinsic and intrinsic
(Bax, Bcl2, cytochrome C) cascades in the hypoxic group. Surprisingly,
LBP increased the expression of proliferative marker (PCNA) and trophic
factor (BDNF) in the hypoxic group.
Conclusion: LBP are neuroprotective against CIH-induced hippocampal
injury and may facilitate CIH-induced neurogenesis.
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CARDIOPROTECTIVE EFFECTS OF TOTAL FLAVONES OF
ELSHOLTZIA SPLENDENS ON ANOXIA/REOXYGENATION
INDUCED INJURY IN H9c2 RAT CARDIOMYOBLAST CELLS

HAY FEVER AND HYPERTENSION IN THE US ADULT
POPULATION

Z Li, L Zhao, LB Qian, ZG Ye, Q Xia, HP Wang
Department of Physiology, Zhejiang University School of Medicine,
Hangzhou, China
Objective: The present study was performed to investigate the effect of
total flavones of Elsholtzia splendens (TFES) in the H9c2 rat cardiomyoblast
cell line subjected to anoxia/reoxygenation and the underlying mechanism.
Methods: H9c2 cells were pretreated with or without TFES (0.001, 0.01,
0.1 mg/ml) for 4 h, and then were cultured in the medium pre-saturated with
5% CO2 + 95% N2 for 6 h to simulate anoxia. The incubator chamber was
ventilated with 5% CO2 + 95% N2 during the whole anoxia. After that, cells
were re-oxygenated in normal medium with 95% O2 + 5% CO2 for 2 h. At
the end of reoxygenation, the cell viability was assayed using MTT method.
Cell lactate dehydrogenase (LDH) release, total-superoxide dismutase
(T-SOD) activity and malondialdehyde (MDA) level were determined using
commercial kits.
Results: Administration with TFES (0.001, 0.01, 0.1 mg/ml) produced a
dose-dependent reduction in the cell death, LDH release and MDA
production induced by anoxia/reoxygenation in H9c2 cells. In addition, the
inhibition of T-SOD activity induced by hypoxia/reoxygenation was
markedly reversed by TFES (0.01, 0.1 mg/ml) but not by 0.001 mg/ml TFES.
Conclusion: Treatment with TFES (0.01, 0.1 mg/ml) for 4 h protected H9c2
cells against anoxia/reoxygenation induced injuries, which may be related
to enhancing SOD activity and reducing oxidative stress.

C Li, CL Cheung, TT Cheung, NR Samaranayake, BMY Cheung
Department of Medicine, The University of Hong Kong, Hong Kong
Purpose: Hypertension is associated with inflammation. Whether the
inflammation caused by allergic diseases such as allergic rhinitis can predispose
to hypertension is controversial. Therefore, we studied the association between
hay fever and hypertension in the United States National Health and Nutrition
Examination Survey (NHANES).
Methods: We analyzed data on 1883 men and 2029 women in NHANES 20052006. We included participants aged 20 years or older who had valid data on
hay fever and hypertension.
Results: 13.5% of the participants had a previous diagnosis of hay fever and
36.2% of them had hypertension. There were ethnic differences in the prevalence
of previous hay fever diagnosis (P<0.001) and hypertension (P<0.001). There
was no significant association between previous hay fever diagnosis and
hypertension in men in any age group. The association between previous hay
fever diagnosis and hypertension in women was significant in those aged 20-39
years (OR=2.59, 95%CI=1.26-5.30, P=0.013). The association between previous
hay fever diagnosis and hypertension in women aged form 20-39 years remained
significant after adjustment for age, race and body mass index (OR=2.74,
95%CI=1.48-5.06, P=0.003). After further adjustment for physical activity,
alcohol consumption and smoking, the association was not attenuated (OR=
2.68, 95%CI=1.38-5.18, P=0.006). Further adjustment for liver enzymes,
C-reactive protein and IgE level attenuated the association slightly (OR=2.72,
95%CI=1.19-6.22, P=0.021).
Conclusions: In this nationally representative population-based survey, previous
hay fever diagnosis is not significantly associated with hypertension in adults
except for young women aged 20-39. Further work is needed to confirm that
this is a true association.

CP7.
TELMISARTAN AMELIORATES OXIDATIVE STRESS AND
APOPTOSIS IN THE LIVER OF RATS EXPOSED TO
CHRONIC INTERMITTENT HYPOXIA
JF Pan,1 J Xiao,2 GL Tipoe,2 Y Huang,3 ML Fung1
Departments of 1Physiology and 2Anatomy, Li Ka Shing Faculty of Medicine,
The University of Hong Kong; 3School of Biomedical Sciences, The Chinese
University of Hong Kong, Hong Kong
Background and Hypothesis: Recurrent cycles of severe hypoxia and
reoxygenation are a hallmark feature of obstructive sleep apnea (OSA)
syndrome, resulting in chronic intermittent hypoxia (IH) that causes excessive
production of reactive oxygen species and oxidative stress in tissues and
organs. It has been shown that blockade of angiotensin (AT) receptors
alleviated the IH-induced systemic hypertension. However, the mechanistic
involvement of AT receptors in the pathogenesis of liver injury under chronic
IH condition is currently unknown. We hypothesized that the expression of
NADPH oxidase induced by activation of AT receptor type 1 plays a role in
the IH-induced oxidative stress and apoptosis in the rat liver.
Methodology: Adult Sprague-Dawley rats were exposed to air for normoxic
(Nx) control or to normobaric oxygen levels alternating between 5-21%
8 hr/day for IH treatment for 2 weeks. Rats were fed with an AT1 receptor
blocker telmisartan (10 mg/kg body weight), or vehicle daily before the
hypoxic treatment. The mRNA levels of NADPH oxidase subunits (p22phox and NOX-4), the pro-apoptotic genes (BAX and FAS) and anti-apoptotic
gene (Bcl-2) were examined by RT-PCR; the cell apoptosis was detected by
TUNEL assay; also the level of oxidative stress with malondialdehyde (MDA)
in the liver.
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Results: Our results showed that the MDA level and the mRNA levels of
p22-phox, NOX-4, BAX, FAS and also the amount of TUNEL-positive cells
were significantly increased in the hypoxic group, when compared with the
Nx and telmisartan-treated hypoxic (TIH) groups. In addition, the expression
of anti-apoptotic gene Bcl-2 was decreased significantly in the hypoxic group
than those of the Nx and TIH groups.
Summary and Conclusion: Blockade of the AT1 receptor with telmisartan
mitigates oxidative stress and apoptosis in the liver of rats exposed to chronic
IH, thus supporting a pathogenic role of NADPH oxidase induced by AT1
receptor activation in the hepatic injury in chronic IH resembling a severe
OSA condition.

October 2012

55

ICSM, THE SIXTEENTH ANNUAL SCIENTIFIC MEETING
ABSTRACTS
Abstracts for Posters:
P01.
VASODILATING EFFECTS OF ADTM, A NOVEL DERIVATIVE
OF DANSHENSU AND TETRAMETHYLPYRAZINE
RWS Li,1 YQ Wang,2 SMY Lee,3 SW Chan,4 YW Kwan,5 GPH Leung1
Department of Pharmacology and Pharmacy, The University of Hong Kong,
Hong Kong; 2Institute of New Drug Research, Jinan University, Guangzhou,
China; 3Institute of Chinese Medical Sciences, University of Macau, Macao;
4
State Key Laboratory of Chinese Medicine and Molecular Pharmacology,
Department of Applied Biology and Chemical Technology, The Hong Kong
Polytechnic University, Hong Kong; 5School of Biomedical Sciences, The
Chinese University of Hong Kong, Hong Kong

1

Danshen (Radix salviae miltiorrhizae) and ChuanXiong (Ligusticum wallichii)
are two herbal medicines which are widely used in treating cardiovascular
diseases. The active components in Danshen is Danshensu (DSS) while that
in ChuanXiong is tetramethylpyrazine (TMP). Recently, we have synthesized
a novel chemical called ADTM, which is a synthetic dimer of TMP and
DSS, in which the hydroxyl groups on DSS are acetylated for enhancing its
chemical stability. In this study, the effect of ADTM on the dilation of rat
mesenteric arteries was investigated.

and ODQ (a soluble guanylyl cyclase inhibitor). In addition, the vasodilating
effect of ADTM was not reduced by SQ 22536 (an adenylate cyclise
inhibitor), indicating that adenylate cyclase/cAMP-dependent pathway was
not involved. The ADTM-induced vasodilation was not linked to potassium
channels since the effect of ADTM was not reduced by iberiotoxin (a big
conductance Ca2+-activated K + channel blocker), glibencalmide (a ATPsensitive K + channel blocker), 4-aminopyridine (a voltage-activated K +
channel blocker), barium chloride (an inward rectifier K+ channel blocker)
and tetraethylammonium (a non-specific K+ channel blocker). In contrast,
the potassium chloride-induced and calcium chloride-induced contractions
were attenuated by 65.6±4.0% and 43.4±4.1%, respectively, by 100 µM
ADTM, reflecting that the vasodilating effect of ADTM might be the result
of blockade of Ca2+ channels in the vascular smooth muscle cells.
In summary, our study demonstrated that ADTM is a novel vasodilator, which
probably works by blocking the voltage-dependet Ca2+ channels in the vascular
smooth muscle cells. The vasodilating effect of ADTM is stronger than its
parent compounds DSS and TMP.

The results showed that the rat mesenteric arteries were dilated by ADTM
in a dose-dependent manner, with an IC 50 value of 133±1.3 µM. The
vasodilating effect of ADTM was more potent than DSS, TMP and the
combination of DSS and TMP. The ADTM-induced vasodilation was not
affected upon the removal of endothelium. Moreover, the vasodilating effect
of ADTM was not reduced by L-NAME (a nitric oxide synthase inhibitor)

P02.
A SINGLE NUCLEOTIDE POLYMORPHISM OF
INTERLEUKIN-6 GENE IS RELATED TO PLASMA
ADRENOMEDULLIN LEVELS
HK Wong,1 KL Ong,2 RYH Leung,1 TH Lam,3 GN Thomas,4,5 KSL Lam,1
BMY Cheung1
1
Department of Medicine, The University of Hong Kong, Hong Kong; 2Lipid
Research Group, Heart Research Institute, Sydney, New South Wales,
Australia; 3Department of Community Medicine and School of Public Health,
The University of Hong Kong, Hong Kong; 4Department of Public Health,
Epidermiology and Biostatistics, University of Birmingham, Birmingham,
The United Kingdom

age and sex (β=-0.096, P=0.034). The association was significant in women
(β=-0.115, P=0.021) but not in men. Amongst all subjects, plasma ADM
level decreased with an increasing number of minor alleles of rs17147230
in multivariate analysis (P=0.034). Compared to subjects with AA genotype,
subjects with TT genotype had a plasma ADM level 12.8% lower (95% CI:
0.6%-23.5%, P=0.041).
Conclusion: Plasma ADM level is related to the SNP rs17147230 in IL-6
gene, and the association appears stronger in women. The effect of the
polymorphism on inflammation and cardiovascular disease remains to be
determined.

Objective: Plasma adrenomedullin (ADM) level is elevated in inflammation
and is associated with cardiovascular diseases. Single nucleotide
polymorphisms (SNPs) in the ADM gene have been found to be associated
with ADM level. The 5'-flanking region of ADM is known to contain a
consensus sequence of the binding site for the nuclear factor for interleukin-6
(IL-6). Therefore, we investigated if plasma ADM level is related to SNPs in
the IL6 gene.
Methods: Plasma ADM level was measured in 476 subjects (236 men, 240
women; mean age 50.9±10.8 years) in the Hong Kong Cardiovascular Risk
Factor Prevalence Study-2 (CRISP2). The subjects were genotyped for three
tagging SNPs in the IL-6 gene.
Results: The minor allele frequencies of the IL-6 SNPs rs17147230,
rs1800796 and rs2069837 were 41.8%, 20.0% and 15.4% respectively. The
SNP rs17147230, was associated with plasma ADM level after adjusting for
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UPREGULATED TRPM2 AND ITS POTENTIAL ROLE IN
NEOINTIMAL HYPERPLASIA
XC Ru,1 S Wan,2 Y Huang,1 XQ Yao1
1
Li Ka Shing Institute of Health Sciences and School of Biomedical Sciences;
and 2Department of Surgery, The Chinese University of Hong Kong, Hong
Kong

muscle cells. These results suggest that TRPM2 is involved in neointimal
hyperplasia and that blocking TRPM2 could be a way to prevent vascular
wall thickening.

A hallmark in atherosclerosis is progressive intimal thickening, which leads
to occlusive vascular disease such as myocardial infarction and stroke. A
causation of neointimal hyperplasia is the migration and proliferation of smooth
muscle cells, in which reactive oxygen species (ROS) play an important role.
This study was designed to investigate the involvement of TRPM2, a member
of the transient receptor potential superfamily, in neointimal hyperplasia.
Neointimal hyperplasia of rat femoral artery was induced by cuff placement.
The TRPM2 expression and ROS generation were detected. The effect of
TRPM2 inhibitors on neointimal hyperplasia of cultured human saphenous
veins, and on proliferation and migration of primary rat aortic smooth muscle
cells was further examined. It was found that arteries with cuff placement for
14 days showed distinct intimal thickening. The neointima area displayed an
enhanced cell cycle activity and upregulated TRPM2 expression. ROS
generation was dramatically increased in the neointima and media layer of
arteries after cuff placement. After culture for 14 days, the human saphenous
veins clearly showed neointimal hyperplasia, which was markedly reduced
by in vitro treatment with TM2E3, a specific TRPM2-blocking antibody, or
2-aminoethoxydiphenyl borate, a chemical blocker. Both TM2E3 and
2-aminoethoxydiphenyl borate inhibited hydrogen peroxide-induced
proliferation and wound-induced migration in primary rat aortic smooth

P04.
ENDOTHELIUM-DEPENDENT AND DIRECT RELAXATION
INDUCED BY TOTAL FLAVONOIDS OF ELSHOLTZIA
SPLENDENS IN RAT THORACIC AORTA
LB Qian,1 L Zhao,2 XY Li,2 Z Li,2 Y Lu,2 GL Zhang, 2 HY Peng, 2 ZG Ye,2
Q Xia,2 HP Wang2
1
Clinical Research Center, 2nd Affiliated Hospital, Zhejiang University
School of Medicine; 2Department of Physiology, Zhejiang University School
of Medicine, China
Objective: To explore the vasoactive effects of total flavonoids of Elsholtzia
splendens (TFES) and its underlying mechanisms on the rat thoracic aorta.
Methods: The tension in isolated ring preparations of thoracic aortas from
Sprague-Dawley rats was measured isometrically. The NO synthase (NOS)
activity of isolated ring preparations was measured by NOS kits.
Results: TFES (5-200 µg/ml) caused a concentration-dependent relaxation
on endothelium-intact rings precontracted by phenylephrine (PE, 10-6 M) or
a high level of K+ (6×10-2 M). This vasorelaxation was not abolished but
reduced significantly by removal of endothelium. Nω-nitro-L-arginine methyl
ester hydrochloride ( L -NAME) (10 -4 M), 1H-[1,2,4] oxadiazolo[4,2-α]
quinoxalin-1-one (ODQ) (5×10-4 M) significantly inhibited the effect of TFES.
Meanwhile, aortic NOS activity in TFES group was markedly elevated versus
the control. However, indomethacin did not alter TFES effect.
Tetraethylammonium, BaCl 2 and 4-aminopyridine also did not alter the
vascular effect of TFES, but glibenclamide significantly attenuated its
vasodilation. TFES reduced PE-induced transient contraction in Ca2+-free
Krebs-Henseleit solution, and the accumulative Ca2+-induced contraction.
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Conclusion: It is concluded that TFES induces both endothelium-dependent
and independent relaxation in rat thoracic aorta. NO/cGMP-mediated pathway
is likely involved in the endothelium-dependent relaxation, whereas inhibition
of voltage-dependent Ca 2+ channel, receptor-operated Ca 2+ channel,
intracellular Ca2+ release and activation of KATP contribute in part to the
endothelium-independent relaxation.
Acknowledgement: This study was supported by grants from the Department
of Science and Technology of Zhejiang Province, China (2011C23105,
2012C33088).
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EFFECTS OF HYPOOSMOLARITY ON CANONICAL
TRANSIENT RECEPTOR POTENTIAL 5 ACTIVITY IN RAT
AORTIC ARCH BARORECEPTOR NEURONS
YW Tjong, XQ Yao
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong
Kong
Aortic arch baroreceptor is a major arterial baroreceptor which plays an
essential role in regulation of arterial blood pressure. Yet the molecular
identity of the aortic arch baroreceptor sensor remains unclear. Canonical
Transient Receptor Potential 5 (TRPC5) is a member of the seven mammalian
TRPC cationic channels respond to mechanical stress including
hypoosmolarity. It was found that TPRC5 is expressed in aortic arch
baroreceptor neurons. We examined the hypothesis that TPRC5 was involved
in pressure sensing in baroreceptor neurons. Whole-cell patch clamping study
was performed on the cultured rat nodose baroreceptor neurons isolated from
the left nodose ganglion. Gadolinium ion (Gd3+, 20 µM) was included in the
bath solution to potentiates TRPC5 activity and to block other cation channels.
A whole-cell cationic current was substantially increased in hypotonic
condition (240 mOsm) when compared with isotonic condition (300 mOsm).
Pretreatment of anti-TRPC5 blocking antibody T5E3 (15 µg/ml) abolished
the hypoosmolarity-activated current, whereas perimmmune IgG (15 µg/ml)
had no effect. To further verify the mechanosensitivity of TRPC5, the nodose
ganglion neurons were transiently tranfected with TPRC5 (6 mg/ml) by
electroporation. Hypoosmolarity stimulated a whole-cell cation current in
TRPC5-overexpressing neurons. Pretreatment of TRPC5 inhibitor
2-aminoethoxydiphenyl borate (2APB, 100 µM, 10 min) markedly reduced
this whole cell current. Taken together, these results suggest that TRPC5 is
involved in mechanosensing at the aortic arch baroreceptor.

P06.
THE FUNCTIONAL ROLE OF TRPM2 CHANNELS IN H2O2INDUCED CA2+ INFLUX AND CELL APOPTOSIS IN H5V
ENDOTHELIAL CELLS
L Sun,1 HY Yau,1 WY Wong,1 RA Li,2 Y Huang,1 XQ Yao1
1
Li Ka Shing Institute of Health Sciences and School of Biomedical Sciences,
The Chinese University of Hong Kong; 2 Stem Cell and Regenerative
Medicine Consortium, The University of Hong Kong, Hong Kong
Melastatin-like transient receptor potential channel 2 (TRPM2) is an oxidantsensitive cationic non-selective channel that is expressed in mammalian
vascular endothelium. I used murine heart microvessel endothelial cell line
H5V to investigate the role of TRPM2 channels in H 2O 2-induced Ca 2+
responses and apoptosis. A TRPM2 blocking antibody channel (TM2E3),
which targets the E3 region near the ion permeation pore of TRPM2, was
developed. Treatment of H5V cells with TM2E3 reduced the Ca2+ responses
to H2O2. Suppressing TRPM2 expression using TRPM2-specific short hairpin
RNA (shRNA) had similar inhibitory effect in H2O2-induced Ca2+ responses.
H2O2-induced apoptotic cell death in H5V cells was examined using MTT
assay, DNA ladder formation analysis, and DAPI-based nuclear DNA
condensation assay. Based on these assays, TM2E3 and TRPM2-specific
shRNA both showed protective effect on H2O2-induced apoptotic cell death.
In contrast, overexpression of TRPM2 in H5V cells increased the Ca 2+
responses to H2O2 and aggravated the apoptotic cell death in response to H2O2.
These findings strongly suggest that the TRPM2 channel mediates Ca 2+
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overload in response to H2O2 and contributes to oxidant-induced apoptotic
cell death in vascular endothelial cells. I also examined the downstream
cascades of TRPM2 activation and explored whether caspase-3, -8 and -9
were involved in this process. My data indicates that H 2O 2-induced cell
apoptosis through both intrinsic and extrinsic apoptotic pathways, leading to
activation of caspases-3. Furthermore, TRPM2 played an essential role in
the process. Together, my data suggest that TRPM2 mediates H2O2-induces
endothelial cell death and that down-regulating endogenous TRPM2 could
be a means to protect the vascular endothelial cells from apoptotic cell death.
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FUNCTIONAL ROLE OF VANILLOID TRANSIENT
RECEPTOR POTENTIAL 2 CHANNEL IN HUMAN INDUCED
PLURIPOTENT STEM-CELL MODEL OF HUTCHINSON
GILFORED PROGERIA SYNDROME
CY Lo,1 YW Tjong,1 JCY Ho,2 HF Tse,2,3 XQ Yao1
1
School of Biomedical Sciences, The Chinese University of Hong Kong;
2
Division of Cardiology, Department of Medicine, The University of Hong
Kong, Queen Mary Hospital; 3Research Centre of Heart, Brain, Hormone
and Healthy Ageing, Li Ka Shing Faculty of Medicine, The University of
Hong Kong, Hong Kong

General cation channel blocker ruthenium red (20 µM) and specific TRPV2
channel inhibitor Transilast (100 µM) markedly attenuated hyptonicityinduced [Ca2+]i elevation in HGPS-iPSC ECs. Taken together, these results
suggested that up-regulated TRPV2 in HGPS-iPSC ECs is involved in
elevation of [Ca2+]i by osmotic pressure changes.

Hutchinson-Gilford Progeria syndrome (HGPS) is a severe genetic disorder
characterized by premature aging including skin, musculoskeletal
cardiovascular systems. However, the pathogenesis of HGPS is unknown.
Vanilloid transient receptor potential channels (TRPV) are calciumpermeable non-selective cation channels that act as cellular sensor respond
to osmolarity, membrane stretch which thought to be related to cardiovascular
diseases. The aim of our present study is to examine the expression and
functional role of TRPV channels in Induced pluripotent stem cells derived
endothelial-like cells (iPSC-ECs) from HGPS patient. Semi-quantitative RTPCR revealed that the relative expression of TRPV2 in HGPS-iPSC ECs
was significantly higher than that in control IMR90-iPSC ECs. We then
examined the possible functional role of TRPV2. Then we applied the
hypotonic osmotic solution to iPSC-ECs while measuring intracellular
calcium ([Ca2+]i). Perfusion of hypotonic solution caused transient [Ca2+]i
elevation in both groups and [Ca2+]i rise was sustained in HGPS-iPSC ECs.

P08.
EFFECTS OF VITAMINS K 2 AND D 3 ON BONE MATRIX
MINERALIZATION OF OSTEOBLASTS OF OBESE/
DIABETIC (db+/db+) MICE
CCW Poon, 1 MWK Tse, 1 ALS Au, 1 SK Kong, 2 HP Ho, 3 GPH Leung, 4
YW Kwan1
1
School of Biomedical Sciences, Faculty of Medicine; 2School of Life
Sciences, Faculty of Science; 3Department of Electronic Engineering, Faculty
of Engineering, The Chinese University of Hong Kong; and 4Department of
Pharmacology and Pharmacy, Faculty of Medicine, The University of Hong
Kong, Hong Kong
Background and Objective: Patients with Type 1 and Type 2 diabetes
mellitus (DM) have a higher risk of bone fractures, particularly at the hip.
Previous studies suggested that both altered leptin level and calcium
homeostasis are responsible for type 2 DM-associated osteoporosis. This study
was designed to assess the effects, in vitro, of vitamin K2 and vitamin D3,
applied alone or in combination, on osteoblasts (bone building cells).
Methods: C57BL/KsJ (female; 4-6 months old) lean/control (db+/m+) and
obese/diabetic (db +/db +) (leptin receptor-deficient) mice were used.
Osteoblasts harvested from the iliac crests (both left and right) were cultured
and randomly assigned into control (drug-free) and drug treated groups
(vitamin K2 and vitamin D3 (1 and 10 nM), alone or in combination, for 7, 14
and 21 days) for the determination of osteoblasts differentiation and
mineralization (alkaline phosphatase activity and calcium-sensing receptor
(CaSR) levels).
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Results: ALP activity and protein expression of CaSR were significantly
lower in osteoblasts of db+/db+ mice compared to db+/m+ mice. Vitamin K2
and vitamin D3 caused a concentration- and time-dependent increase of CaSR
levels and ALP activities, with a greater magnitude of increase was detected
when both vitamins were applied in combination, in osteoblasts of both strains
of mice.
Conclusion: Our results indicate that ALP activity and CaSR expression
were lower in osteoblasts of db+/db+ mice compared to db+/m+ mice. More
importantly, vitamin K 2 and vitamin D 3, when applied in combination,
enhanced mineralization of osteoblasts of both strains of mice with a greater
magnitude of increase was observed in db+/db+ mice.
Acknowledgement: Provision of post-graduate studentship to Miss CCW
Poon by the School of Biomedical Sciences (The Chinese University of Hong
Kong) is acknowledged.
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FLUOXETINE-INDUCED CARDIAC DEPRESSION IN
ISOLATED PERFUSED RAT HEART
MY Lee
Department of Occupational Therapy, College of Health Science, Honam
University, Gwangju, Republic of Korea
Introduction: Fluoxetine is a widely used antidepressant compound and its
action is primarily attributed to selective serotonin reuptake inhibitor (SSRI)
in the central nervous system. SSRI drugs had been believed to cause fewer
cardiovascular side effects. However, there are an increasing number of case
reports on dysrhythmias, such as atrial fibrillation or bradycardia. Since an
intracellular Mg2+ concentration ([Mg2+]i) should be maintained within a
relatively narrow concentration range in order to ensure the proper functioning
of the heart, Mg2+ is often lost from cardiac cells during the development of
heart disease, which may exacerbate the damage caused by disease. Our
objective was to investigate an effect of fluoxetine on cardiac functions and
to investigate alteration of Mg2+ homeostasis.
Materials and Methods: Left ventricular development pressure (LVDP),
maximum velocity of the change in pressure (dP/dtmax), minimum velocity
of the change in pressure (dP/dtmin), heart rate (HR) and Mg2+ efflux ([Mg2+]e)
were measured simultaneously in isolated rat hearts with Langendorff's
perfusion system. [Mg2+]i was measured using Mag-fura 2 AM in H9c2 cell.
The activation of ERK 1/2 was analyzed by Western blot. Electrocardiogram
in anesthetic rats was recorded using a BIOPAC® system.

Results: Fluoxetine produced reversible dose-dependent decreases in the
LVDP, dP/dtmax and dP/dtmin in the perfused hearts of rat. After wash out,
[Mg2+]e was significantly increased, accompanied by decreases in HR. In
H9c2 cells, fluoxetine produced significant activation of ERK 1/2 and a dosedependent increase in the [Mg2+]i, which were inhibited by pretreatment of
PD98059, an ERK 1/2 inhibitor. Phosphorylated-ERK 1/2 in isolated hearts
were increased by treatment of fluoxetine. Fluoxetine caused change of ECG
including prolongation of PR, R-R and QT interval.
Conclusions: Fluoxetine can produce cardiac depression partly through an
increase in [Mg2+]i and [Mg2+]e accompanied by the activation of ERK 1/2.

P10.
RELATION OF HYPOTHERMIA AND MAGNESIUM IN
HEART
MY Lee,1 SJ Lee,2 JS Kim,3 HS Kang,3 SJ Kim3
Department of Occupational Therapy, College of Health Science, Honam
University, Gwangju; 2Korea Basic Science Institute Jeonju Center; 3College
of Veterinary Medicine, Chonbuk National University, Jeonju, Republic of
Korea

1

Introduction: Deep hypothermia (4°C) is widely used in conjunction with
cardioplegia to minimize neurologic and cardiac damage during cardiac
surgery. However, during the subsequent rewarming and reperfusion many
destructive processes result in inevitable post-ischemic myocardial injuries
due to Ca2+ overload. Mild hypothermia (core temperature 30-35°C) has been
shown to protect the beating rabbit heart against infarction and donor hearts
from pig kept in a beating state under mild hypothermia (32-34°C) showed
improved recovery of metabolic and mechanical functions compared with
traditional cold storage. To ensure the proper function of the heart, intracellular
Mg2+ concentrations ([Mg2+]i) should be maintained within a relatively narrow
concentration range because Mg2+ plays a vital role in the mechanical and
electrical properties of the heart. Our aim was to investigate Mg2+ regulation
in heart during mild hypothermia (30°C to 35°C).
Materials and Methods: [Mg2+]i, intracellular Na+ concentration ([Na+]i),
total Mg efflux ([Mg]e) and extracellular signal-regulated kinases 1/2 (ERK
1/2) were measured in isolated papillary muscle, cardiac cell and perfused
heart from guinea-pig during mild hypothermia.
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Results: In beating papillary muscle of the guinea pig, [Mg 2+ ]i was
significantly increased by hypothermia (34°C and 30°C), accompanied by an
increase in [Na + ]i, a large positive inotropic effect, depolarization of
membrane potential and prolongation of action potential duration. In addition,
mild hypothermia enhanced the increase in [Mg 2+ ]i induced by high
extracellular Mg2+ concentration ([Mg2+]o). The rate of [Mg]e in perfused
heart was significantly attenuated by hypothermia. Free [Mg2+]o provoked
the activation of ERK1/2 in cardiac cells, which was attenuated at 30°C
compared to that at 37°C.
Conclusions: These results suggested that the mild hypothermia could
produce an increase in [Mg2+]i in guinea-pig heart by stimulation of Mg2+
influx and attenuation of Mg2+ efflux, accompanied by attenuation of ERK1/
2 activation.
(Mun-Young Lee, Sei-Jin Lee equally contributed to this study.)
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EFFECT OF BLOOD MAGNESIUM AND CALCIUM BY
FORCED HYPER- AND HYPO-VENTILATION
MY Lee,1 SJ Lee,2 JS Kim,3 SJ Kim,3 HS Kang3
Department of Occupational Therapy, College of Health Science, Honam
University, Gwangju; 2Korea Basic Science Institute Jeonju Center; 3College
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Korea
1

Introduction: It was well-known that respiratory change alters blood pH,
PaCO2, HCO3, and many ions level including phosphorus, potassium and
calcium. Although some researches had investigated total magnesium during
hyperventilation or hypoventilation, magnesium ion (Mg2+) has been given
little attention compared with potassium and calcium ion. Magnesium exists
in biological fluids in the ionized and nonionized form, of which only former
has physiological activity. In the present study, we attempted to determine
the values of blood ionized Ca2+ (iCa2+), Mg2+ (iMg2+), and the ratio of iCa2+/
iMg2+ during the change of respiration in anesthetized rats.
Materials and Methods: Hyperventilation induced by increase 2 times in
tidal volume and respiratory rate during 10 min in anesthetized rats (male
Sprague-Dawley, 200-250 g). Hypoventilation induced by decrease 1/2 times
in tidal volume and respiratory rate during 10 min in anesthetized rats. Blood
samples were obtained before and after operation and were analyzed whole
blood ions using Nova Stat Profile 8 CRT (NOVA Biomedical Corp, Waltham,
MA, USA) including the blood pH, blood gas compositions and the
concentrations of ionized Na+, Cl-, K+, Ca2+, Mg2+ and lactate. Hematocrit
(Hct) was measured by conductivity. The concentration of HCO 3− was
calculated using the Henderson-Hasselbach equation. The anion gap values
were calculated by the formula; [Na+-(Cl−+HCO3−)].

Results: After hyperventilation, the blood pH, glucose, lactate, partial
O 2 tension (PO2), O 2 saturation (O 2sat; P<0.05), alveolar O 2 (A), partial
O2 tension/fraction of inspired O2 (PO2/FI), iCa2+, and iMg2+ were significantly
increased (P<0.01, n=11, paired t-test). The blood partial CO2 tension (PCO2),
total CO2 (TCO2), HCO3−, base excess of extracellular fluid (BE-ECF), base
excess of blood (BE-B), and iCa 2+ /iMg 2+ were significantly decreased
(P<0.01), although the blood osmolarity (Osm), Hct, hemoglobin (Hb),
O2 content (O2ct), arterial alveolar O2 tension ratio (a/A), Na+, and K+ were
not significantly changed. After hypoventilation, the blood pH, lactate, PO2,
O2ct, O2sat, A, a/A, and iCa2+/iMg2+ were significantly decreased (P<0.01,
n=12). The blood glucose, PCO2, TCO2, HCO3− (P<0.05), and iMg2+ were
significantly increased (P<0.01), although the blood Osm, Hct, Hb, Na+, K+,
and iCa2+ were not significantly changed.
Conclusions: These data suggest that the change of respiration could alter
blood iMg2+, iCa2+ and the ratio of iCa2+/iMg2+ and both hyperventilation and
hypoventilation increased in iMg2+ accompanied with decreasing in the ratio
of iCa2+/iMg2+.
(Mun-Young Lee, Sei-Jin Lee equally contributed to this study.)

P12.
SODIUM-RESTRICTED DIET FOR HEART FAILURE
PATIENTS: AN UPDATE
SY Yau,1 YL Cheung2
1
Open University of Hong Kong; 2Tuen Mun Hospital, Hong Kong

Conclusion: Sodium-restricted diet is recognized to be positively associated
with clinical health outcomes in heart failure patients. Thus, the therapeutic
importance of sodium-restricted diet in heart failure patients is supported.

Introduction: Heart failure is a common cardiovascular disease with high
morbidity and mortality rates. In Hong Kong, the number of deaths due to
heart failure was 817 in year 2010. Also, heart failure remains one of the
primary reasons for hospital admission and readmission. The American Heart
Association recommends sodium-restricted diet for health failure patients
and research supported that sodium-restricted diet prevents worsening of the
heart failure condition. The objective of this study is to provide an update on
the effects of sodium-restricted diet on heart failure patients.
Methods: Search of literature was conducted with multiple databases.
Literature related to the effects of sodium-restricted diet on heart failure
patients were reviewed and summarized.
Results: Research supported that patients who consumed sodium-restricted
diets (less than 3 g/day) showed lower symptoms burdens related to the
disease such as shortness of breath, swelling of legs or ankles, and difficulty
in sleeping. With the compliance of diet recommendation, heart failure
patients demonstrated a decreased rate of hospital admission and readmission,
and a longer cardiac event-free survival than those who did not follow the
diet recommendation. Nevertheless, sodium-restricted diet improved the
severity of sleep apnea caused by fluid retention among heart failure patients.
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NITRIC OXIDE INHIBITS 11,12-EET INDUCED PORCINE
CORONARY ARTERIAL HYPERPOLARIZATION AND
RELAXATION
P Zhang, Y Ma, XQ Yao
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong
Kong

Conclusion: This study uncovers a novel mechanism by which NO inhibits
the action of EETs. We found that 11,12-EET acts on TRPV4-C1-BK Ca
complex to induce VSMC hyperpolarization and vascular relaxation in
porcine small coronary artery, and that NO-cGMP-PKG inhibits 11,12-EETinduced membrane hyperpolarization by acting on TRPC1 component within
the TRPV4-C1-BKCa complex.

Objective: The vascular endothelial cells synthesize and release vasodilators
such as Nitric oxide (NO) and epoxyeicosatrienoic acids (EETs). In normal
physiological state, NO inhibits EETs-mediated vascular relaxation. In this
study, we examined the molecular target of EETs and explored the mechanism
of NO inhibition on EETs in isolated porcine small coronary arterial segments
without endothelium.
Methods and Results: Co-immunoprecipitation and immunohistochemistry
studies demonstrated that TRPV4 (vanilloid transient receptor potential
channel 4), TRPC1 (canonical transient receptor potential channel 1), and
BKCa (large conductance Ca2+-activated K+ channels) physically interact with
each other to form TRPV4-C1-BKCa tri-complex. Isometric force measurement
and sharp microelectrode methods showed that 11,12-EET induced relaxation
and membrane hyperpolarization in porcine small coronary artery, which
were markedly reduced by treatments that inhibit the activity of TRPV4,
TRPC1, or BK Ca . 11,12-EET-induced relaxation and membrane
hyperpolarization were inhibited by 8-Br-cGMP and NO donor S-nitroso-Nacetylpenicillamine (SNAP). This action was markedly reduced by treatments
that suppress the protein kinase G phosphorylation on TRPC1.

P14.
A LOW AST-TO-ALT RATIO PREDICTS NEW-ONSET
DIABETES IN PATIENTS TREATED WITH ATORVASTATIN:
RESULTS FROM THE TREATING TO NEW TARGETS [TNT]
TRIAL)
KL Ong,1,2 M Messig,3 DA DeMicco,3 KA Rye,1,2,4 PJ Barter,1,2 DD Waters5
Heart Research Institute, Sydney, New South Wales, Australia; 2Faculty of
Medicine, University of Sydney, Sydney, New South Wales, Australia;
3
Pfizer, Inc., New York, New York, United States; 4Department of Medicine,
University of Melbourne, Melbourne, Victoria, Australia; 5Division of
Cardiology, San Francisco General Hospital, and the University of California
at San Francisco, San Francisco, California, United States

1

Introduction: Features of the metabolic syndrome such as baseline fasting
glucose, body mass index, hypertension, and fasting triglycerides, are
independent risk factors for new-onset diabetes (NOD) in patients with statin
therapy. As non-alcoholic fatty liver disease has been recognized as the hepatic
manifestation of the metabolic syndrome, this study investigated whether
hepatic markers can predict NOD in patients with statin therapy.
Methods: A total of 7,595 patients without prevalent diabetes at baseline
from the Treating to New Targets (TNT) study were included in this analysis.
In TNT, patients were randomized to atorvastatin 10 or 80 mg/day and
followed for a median of 4.9 years. The associations of alanine
aminotransferase (ALT), aspartate aminotransferase (AST), and AST/ALT
ratio at baseline with NOD were investigated.
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Results: Among 7,595 patients, 659 developed NOD during the follow-up.
Patients with NOD had significantly higher ALT level (17.14±6.69 vs
15.78±5.94 U/l, P<0.001) and lower AST/ALT ratio (0.94±0.25 vs 1.02±0.28,
P<0.001) at baseline than those without NOD. In multivariate analysis, a
lower AST/ALT ratio was an independent predictor of NOD, in addition to
higher fasting glucose, higher body mass index, higher white blood cell
count, and hypertension. The hazard ratios (95% CI) were 0.82 (0.67-0.99),
0.75 (0.60-0.93), and 0.75 (0.59-0.96), respectively, in patients with AST/
ALT ratio in quartiles 2, 3, and 4, compared to those in quartile 1.
Conclusion: AST/ALT ratio at baseline is predictive of NOD in patients
with statin therapy. Further studies are needed to investigate whether this
ratio can be used as a biomarker to monitor the NOD risk in patients taking
statin therapy.
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